The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer

Abstract

Yes-associated protein (YAP) plays a central role in the Hippo pathway, primarily governing cell proliferation, differentiation, and apoptosis. Its significance extends to tumorigenesis and inflammatory conditions, impacting disease initiation and progression. Given the increasing relevance of YAP in inflammatory disorders and cancer, this study aims to elucidate its pathological regulatory functions in these contexts. Specifically, we aim to investigate the involvement and molecular mechanisms of YAP in various inflammatory diseases and cancers. We particularly focus on how YAP activation, whether through Hippo-dependent or independent pathways, triggers the release of inflammation and inflammatory mediators in respiratory, cardiovascular, and digestive inflammatory conditions. In cancer, YAP not only promotes tumor cell proliferation and differentiation but also modulates the tumor immune microenvironment, thereby fostering tumor metastasis and progression. Additionally, we provide an overview of current YAP-targeted therapies. By emphasizing YAP’s role in inflammatory diseases and cancer, this study aims to enhance our understanding of the protein’s pivotal involvement in disease processes, elucidate the intricate pathological mechanisms of related diseases, and contribute to future drug development strategies targeting YAP.

Keywords

cancer / Hippo pathway / inflammatory diseases / Yes-associated protein

References

[1] J. H. Driskill and D. Pan, “Control of Stem Cell Renewal and Fate by YAP and TAZ,” Nature Reviews Molecular Cell Biology 24, no. 12 (2023): 895–911.

[2] H. L Sladitschek-Martens, A. Guarnieri, G. Brumana, et al., “YAP/TAZ Activity in Stromal Cells Prevents Ageing by Controlling cGAS-STING,” Nature 607, no. 7920 (2022): 790–798.

[3] J. Wu, A. M. Minikes, M. Gao, et al., “Intercellular Interaction Dictates Cancer Cell Ferroptosis via NF2-YAP Signalling,” Nature 572, no. 7769 (2019): 402–406.

[4] I. M. Moya, S. A. Castaldo, L. Van den Mooter, et al., “Peritumoral Activation of the Hippo Pathway Effectors YAP and TAZ Suppresses Liver Cancer in Mice,” Science 366, no. 6468 (2019): 1029–1034.

[5] A. Dey, X. Varelas, and K. L. Guan, “Targeting the Hippo Pathway in Cancer, Fibrosis, Wound Healing and Regenerative Medicine,” Nature Reviews. Drug Discovery 19, no. 7 (2020): 480–494.

[6] T. Panciera, L. Azzolin, M. Cordenonsi, and S. Piccolo, “Mechanobiology of YAP and TAZ in Physiology and Disease,” Nature Reviews Molecular Cell Biology 18, no. 12 (2017): 758–770.

[7] A. Totaro, T. Panciera, and S. Piccolo, “YAP/TAZ Upstream Signals and Downstream Responses,” Nature Cell Biology 20, no. 8 (2018): 888–899.

[8] V. Rausch and C. G. Hansen, “The Hippo Pathway, YAP/TAZ, and the Plasma Membrane,” Trends in Cell Biology 30, no. 1 (2020): 32–48.

[9] F. Zanconato, M. Cordenonsi, and S. Piccolo, “YAP and TAZ: A Signalling Hub of the Tumour Microenvironment,” Nature Reviews Cancer 19, no. 8 (2019): 454–464.

[10] L. S. Huang, Z. Hong, W. Wu, et al., “mtDNA Activates cGAS Signaling and Suppresses the YAP-Mediated Endothelial Cell Proliferation Program to Promote Inflammatory Injury,” Immunity 52, no. 3 (2020): 475–486. e475.

[11] L. Shen, P. Hu, Y. Zhang, et al., “Serine Metabolism Antagonizes Antiviral Innate Immunity by Preventing ATP6V0d2-mediated YAP Lysosomal Degradation,” Cell Metabolism 33, no. 5 (2021): 971–987. e976.

[12] V. S. Meli, P. K. Veerasubramanian, T. L. Downing, W. Wang, and W. F. Liu, “Mechanosensation to Inflammation: Roles for YAP/TAZ in Innate Immune Cells,” Science Signaling 16, no. 783 (2023): eadc9656.

[13] V. S. Meli, H. Atcha, P. K. Veerasubramanian, et al., “YAP-mediated Mechanotransduction Tunes the Macrophage Inflammatory Response,” Science Advances 6, no. 49 (2020): eabb8471.

[14] D. Chakravarti, B. Hu, X. Mao, et al., “Telomere Dysfunction Activates YAP1 to Drive Tissue Inflammation,” Nature Communications 11, no. 1 (2020): 4766.

[15] R. Caire, E. Audoux, M. Thomas, et al., “YAP Promotes Cell-autonomous Immune Responses to Tackle Intracellular Staphylococcus aureus in Vitro,” Nature Communications 13, no. 1 (2022): 6995.

[16] D. Wang, Y. Zhang, X. Xu, et al., “YAP Promotes the Activation of NLRP3 Inflammasome via Blocking K27-linked Polyubiquitination of NLRP3,” Nature Communications 12, no. 1 (2021): 2674.

[17] N. Van Sciver, M. Ohashi, N. P. Pauly, et al., “Hippo Signaling Effectors YAP and TAZ Induce Epstein-Barr Virus (EBV) Lytic Reactivation Through TEADs in Epithelial Cells,” PLoS Pathogens 17, no. 8 (2021): e1009783.

[18] Y. Liu, S. Zhuo, Y. Zhou, et al., “Yap-Sox9 Signaling Determines Hepatocyte Plasticity and Lineage-specific Hepatocarcinogenesis,” Journal of Hepatology 76, no. 3 (2022): 652–664.

[19] M. B. Nilsson, H. Sun, J. Robichaux, et al., “A YAP/FOXM1 Axis Mediates EMT-associated EGFR Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components,” Science Translational Medicine 12, no. 559 (2020): eaaz4589.

[20] F. Calvo, N. Ege, A. Grande-Garcia, et al., “Mechanotransduction and YAP-dependent Matrix Remodelling Is Required for the Generation and Maintenance of Cancer-associated Fibroblasts,” Nature Cell Biology 15, no. 6 (2013): 637–646.

[21] A. Barettino, C. Gonzalez-Gomez, P. Gonzalo, et al., “Endothelial YAP/TAZ Activation Promotes Atherosclerosis in a Mouse Model of Hutchinson-Gilford progeria Syndrome,” Journal of Clinical Investigation 134, no. 22 (2024): e173448.

[22] C. G. Hansen, T. Moroishi, and K. L. Guan, “YAP and TAZ: A Nexus for Hippo Signaling and Beyond,” Trends in Cell Biology 25, no. 9 (2015): 499–513.

[23] H. Qiu, J. Liu, Q. Wu, et al., “An in Vitro Study of the Impact of IL-17A and IL-22 on Ciliogenesis in Nasal Polyps Epithelium via the Hippo-YAP Pathway,” Journal of Allergy and Clinical Immunology 154, no. 5 (2024): 1180–1194.

[24] I. T. Stancil, J. E. Michalski, C. E. Hennessy, et al., “Interleukin-6-dependent Epithelial Fluidization Initiates Fibrotic Lung Remodeling,” Science Translational Medicine 14, no. 654 (2022): eabo5254.

[25] K. Yang, J. Xu, M. Fan, et al., “Lactate Suppresses Macrophage Pro-Inflammatory Response to LPS Stimulation by Inhibition of YAP and NF-kappaB Activation via GPR81-Mediated Signaling,” Frontiers in Immunology 11 (2020): 587913.

[26] H. J. Choi, N. E. Kim, B. M. Kim, M. Seo, and J. H. Heo, “TNF-alpha-Induced YAP/TAZ Activity Mediates Leukocyte-Endothelial Adhesion by Regulating VCAM1 Expression in Endothelial Cells,” International Journal of Molecular Sciences 19, no. 11 (2018): 3428.

[27] Y. Lv, K. Kim, Y. Sheng, et al., “YAP Controls Endothelial Activation and Vascular Inflammation through TRAF6,” Circulation Research 123, no. 1 (2018): 43–56.

[28] T. Yuan, R. Zheng, J. Liu, et al., “Role of Yes-associated Protein in Interleukin-13 Induced Nasal Remodeling of Chronic Rhinosinusitis With Nasal Polyps,” Allergy 76, no. 2 (2021): 600–604.

[29] R. A. Symons, F. Colella, F. L. Collins, et al., “Targeting the IL-6-Yap-Snail Signalling Axis in Synovial Fibroblasts Ameliorates Inflammatory Arthritis,” Annals of the Rheumatic Diseases 81, no. 2 (2022): 214–224.

[30] B. Zhong, J. Liu, H. H. Ong, et al., “Hypoxia-reduced YAP Phosphorylation Enhances Expression of Mucin5AC in Nasal Epithelial Cells of Chronic Rhinosinusitis With Nasal Polyps,” Allergy (2024).

[31] N. S. Rachedi, Y. Tang, Y. Y. Tai, et al., “Dietary Intake and Glutamine-serine Metabolism Control Pathologic Vascular Stiffness,” Cell Metabolism 36, no. 6 (2024): 1335–1350. e1338.

[32] C. L. Guo, “Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis,” Frontiers in Cell and Developmental Biology 10 (2022): 862791.

[33] L. Wang, C. Wang, Z. Tao, et al., “Curcumin Derivative WZ35 Inhibits Tumor Cell Growth via ROS-YAP-JNK Signaling Pathway in Breast Cancer,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 460.

[34] C. Bachert, B. Marple, R. J. Schlosser, et al., “Adult Chronic Rhinosinusitis,” Nature Reviews Disease Primers 6, no. 1 (2020): 86.

[35] B. Zhong, J. Du, F. Liu, et al., “Hypoxia-induced Factor-1alpha Induces NLRP3 Expression by M1 Macrophages in Noneosinophilic Chronic Rhinosinusitis With Nasal Polyps,” Allergy 76, no. 2 (2021): 582–586.

[36] B. Zhong, J. J. Seah, F. Liu, L. Ba, J. Du, and Y. Wang, “The Role of Hypoxia in the Pathophysiology of Chronic Rhinosinusitis,” Allergy 77, no. 11 (2022): 3217–3232.

[37] B. Zhong, S. Sun, K. S. Tan, et al., “HIF-1alpha Activates NLRP3 Inflammasome to Regulate Epithelial Differentiation in Chronic Rhinosinusitis,” Journal of Allergy and Clinical Immunology 152, no. 6 (2023): 1444–1459.

[38] S. He, J. Wu, D. Han, et al., “Differential Expression Profile of Plasma Exosomal microRNAs in Chronic Rhinosinusitis With Nasal Polyps,” Experimental Biology and Medicine (Maywood, N.J.) 247, no. 12 (2022): 1039–1046.

[39] X. Liu, X. Tong, L. Zou, et al., “A Genome-wide Association Study Reveals the Relationship Between human Genetic Variation and the Nasal Microbiome,” Communications Biology 7, no. 1 (2024): 139.

[40] H. Qiu, J. Liu, Q. Wu, et al., “An in Vitro Study of the Impact of IL-17A and IL-22 on Ciliogenesis in Nasal Polyps Epithelium via the Hippo-YAP Pathway,” Journal of Allergy and Clinical Immunology 154, no. 5 (2024): 1180–1194.

[41] H. Deng, Y. Sun, W. Wang, et al., “The Hippo Pathway Effector Yes-associated Protein Promotes Epithelial Proliferation and Remodeling in Chronic Rhinosinusitis With Nasal Polyps,” Allergy 74, no. 4 (2019): 731–742.

[42] T. Yuan, R. Zheng, X. M. Zhou, et al., “Abnormal Expression of YAP Is Associated with Proliferation, Differentiation, Neutrophil Infiltration, and Adverse Outcome in Patients with Nasal Inverted Papilloma,” Frontiers in Cell and Developmental Biology 9 (2021): 625251.

[43] X. Jiang, L. Shu, Y. Liu, et al., “YES-associated Protein-regulated Smad7 Worsen Epithelial Barrier Injury of Chronic Sinusitis With Nasal Polyps,” Immunity, Inflammation and Disease 11, no. 6 (2023): e907.

[44] Y. Zhou, Y. Jiang, W. Peng, M. Li, H. Chen, and S. Chen, “The Diverse Roles of YAP in the Regulation of human Nasal Epithelial Remodeling,” Tissue & Cell 72 (2021): 101592.

[45] J. Zhan, H. Zhan, J. Zheng, X. Wei, and Y. Fu, “YAP1 expression in Nasal Polyps and Its Relationship With Epithelial Mesenchymal Transition,” American Journal of Translational Research 13, no. 6 (2021): 6568–6575.

[46] H. Deng, M. Li, R. Zheng, et al., “YAP Promotes Cell Proliferation and Epithelium-Derived Cytokine Expression via NF-kappaB Pathway in Nasal Polyps,” Journal of Asthma and Allergy 14 (2021): 839–850.

[47] S. T. Holgate, S. Wenzel, D. S. Postma, S. T. Weiss, H. Renz, and P. D. Sly, “Asthma,” Nature Reviews Disease Primers 1, no. 1 (2015): 15025.

[48] B. N. Lambrecht, H. Hammad, and J. V. Fahy, “The Cytokines of Asthma,” Immunity 50, no. 4 (2019): 975–991.

[49] F. A. Vieira Braga, G. Kar, M. Berg, et al., “A Cellular Census of human Lungs Identifies Novel Cell States in Health and in Asthma,” Nature Medicine 25, no. 7 (2019): 1153–1163.

[50] R. L. Miller, M. H. Grayson, and K. Strothman, “Advances in Asthma: New Understandings of Asthma’s Natural History, Risk Factors, Underlying Mechanisms, and Clinical Management,” Journal of Allergy and Clinical Immunology 148, no. 6 (2021): 1430–1441.

[51] R. Kaur and G. Chupp, “Phenotypes and Endotypes of Adult Asthma: Moving Toward Precision Medicine,” Journal of Allergy and Clinical Immunology 144, no. 1 (2019): 1–12.

[52] H. Xie, L. Wu, Z. Deng, Y. Huo, and Y. Cheng, “Emerging Roles of YAP/TAZ in Lung Physiology and Diseases,” Life Sciences 214 (2018): 176–183.

[53] W. Tang, M. Li, X. Yangzhong, et al., “Hippo Signaling Pathway and respiratory Diseases,” Cell Death Discovery 8, no. 1 (2022): 213.

[54] L. E. Fodor, A. Gezsi, L. Ungvari, et al., “Investigation of the Possible Role of the Hippo/YAP1 Pathway in Asthma and Allergy,” Allergy, Asthma & Immunology Research 9, no. 3 (2017): 247–256.

[55] F. S. Yuliani, J. Y. Chen, W. H. Cheng, H. C. Wen, B. C. Chen, and C. H. Lin, “Thrombin Induces IL-8/CXCL8 Expression by DCLK1-dependent RhoA and YAP Activation in human Lung Epithelial Cells,” Journal of Biomedical Science 29, no. 1 (2022): 95.

[56] H. Xiao, Q. N. Zhang, Q. X. Sun, L. D. Li, S. Y. Xu, and C. Q. Li, “Transcriptomic Analysis Reveals a Link between Hippo Signaling Pathway and Macrophages in Lungs of Mice With OVA-Induced Allergic Asthma,” Journal of Inflammation Research 15 (2022): 423–437.

[57] E. K. Persson, K. Verstraete, I. Heyndrickx, et al., “Protein Crystallization Promotes Type 2 Immunity and Is Reversible by Antibody Treatment,” Science 364, no. 6442 (2019): eaaw4295.

[58] X. Li, S. Guerra, J. G. Ledford, et al., “Low CC16 mRNA Expression Levels in Bronchial Epithelial Cells Are Associated With Asthma Severity,” American Journal of Respiratory and Critical Care Medicine 207, no. 4 (2023): 438–451.

[59] R. Guidi, D. Xu, D. F. Choy, et al., “Steroid-induced Fibroblast Growth Factors Drive an Epithelial-mesenchymal Inflammatory Axis in Severe Asthma,” Science Translational Medicine 14, no. 641 (2022): eabl8146.

[60] L. Yuan, H. Liu, X. Du, et al., “Airway Epithelial ITGB4 Deficiency Induces Airway Remodeling in a Mouse Model,” Journal of Allergy and Clinical Immunology 151, no. 2 (2023): 431–446. e416.

[61] D. Wu, W. Jiang, C. Liu, et al., “CTNNAL1 participates in the Regulation of Mucus Overproduction in HDM-induced Asthma Mouse Model Through the YAP-ROCK2 Pathway,” Journal of Cellular and Molecular Medicine 26, no. 5 (2022): 1656–1671.

[62] M. L. Bu, M. H. Li, M. Feng, J. R. Wang, and L. Sun, “Poly(I:C) Exacerbates Airway Goblet Cell Hyperplasia and Lung Inflammation in HDM-Exposed Balb/C Mice by YAP/FOXM1 Pathway,” International Archives of Allergy and Immunology 184, no. 7 (2023): 707–719.

[63] I. T. Stancil, J. E. Michalski, D. Davis-Hall, et al., “Pulmonary Fibrosis Distal Airway Epithelia Are Dynamically and Structurally Dysfunctional,” Nature Communications 12, no. 1 (2021): 4566.

[64] J. J. Gokey, A. Sridharan, Y. Xu, et al., “Active Epithelial Hippo Signaling in Idiopathic Pulmonary Fibrosis,” JCI Insight 3, no. 6 (2018): e98738.

[65] J. Gao and W. Wang, “Tripterine Alleviates Lipopolysaccharide-induced Airway Epithelial Barrier Dysfunction Through Suppressing the Hippo Pathway,” RSC Advances 8, no. 69 (2018): 39696–39702.

[66] L. B Mostaco-Guidolin, E. T. Osei, J. Ullah, et al., “Defective Fibrillar Collagen Organization by Fibroblasts Contributes to Airway Remodeling in Asthma,” American Journal of Respiratory and Critical Care Medicine 200, no. 4 (2019): 431–443.

[67] X. O. Zhao, M. Lampinen, O. Rollman, C. P. Sommerhoff, A. Paivandy, and G. Pejler, “Mast Cell Chymase Affects the Functional Properties of Primary human Airway Fibroblasts: Implications for Asthma,” Journal of Allergy and Clinical Immunology 149, no. 2 (2022): 718–727.

[68] Q. Sun, L. Fang, M. Roth, et al., “Bronchial Thermoplasty Decreases Airway Remodelling by Blocking Epithelium-derived Heat Shock Protein-60 Secretion and Protein Arginine Methyltransferase-1 in Fibroblasts,” European Respiratory Journal 54, no. 6 (2019): 1900300.

[69] N. Miyashita, M. Horie, H. I. Suzuki, et al., “FOXL1 Regulates Lung Fibroblast Function via Multiple Mechanisms,” American Journal of Respiratory Cell and Molecular Biology 63, no. 6 (2020): 831–842.

[70] L. R. Teegala, R. Gudneppanavar, E. E. Sabu Kattuman, et al., “Prostaglandin E(2) Attenuates Lung Fibroblast Differentiation via Inactivation of Yes-associated Protein Signaling,” Faseb Journal 37, no. 10 (2023): e23199.

[71] F. Wu, X. Li, M. Looso, et al., “Spurious Transcription Causing Innate Immune Responses Is Prevented by 5-hydroxymethylcytosine,” Nature Genetics 55, no. 1 (2023): 100–111.

[72] R. Saunders, H. Kaul, R. Berair, et al., “DP(2) Antagonism Reduces Airway Smooth Muscle Mass in Asthma by Decreasing Eosinophilia and Myofibroblast Recruitment,” Science Translational Medicine 11, no. 479 (2019): eaao6451.

[73] C. Yon, D. A. Thompson, J. A. Jude, R. A. Panettieri Jr., and D. Rastogi, “Crosstalk Between CD4(+) T Cells and Airway Smooth Muscle in Pediatric Obesity-related Asthma,” American Journal of Respiratory and Critical Care Medicine 207, no. 4 (2023): 461–474.

[74] S. V. Akkenepally, D. J. K. Yombo, S. Yerubandi, et al., “Interleukin 31 Receptor Alpha Promotes Smooth Muscle Cell Contraction and Airway Hyperresponsiveness in Asthma,” Nature Communications 14, no. 1 (2023): 8207.

[75] J. Zhou, F. Xu, J. J. Yu, and W. Zhang, “YAP Is Up-regulated in the Bronchial Airway Smooth Muscle of the Chronic Asthma Mouse Model,” International Journal of Clinical and Experimental Pathology 8, no. 9 (2015): 11132–11139.

[76] J. Fu, M. Zheng, X. Zhang, et al., “Fibulin-5 Promotes Airway Smooth Muscle Cell Proliferation and Migration via Modulating Hippo-YAP/TAZ Pathway,” Biochemical and Biophysical Research Communications 493, no. 2 (2017): 985–991.

[77] L. Liu, C. Zhai, Y. Pan, et al., “Sphingosine-1-phosphate Induces Airway Smooth Muscle Cell Proliferation, Migration, and Contraction by Modulating Hippo Signaling Effector YAP,” American Journal of Physiology. Lung Cellular and Molecular Physiology 315, no. 4 (2018): L609–L621.

[78] Z. Deng, H. Xie, W. Cheng, et al., “Dabigatran Ameliorates Airway Smooth Muscle Remodeling in Asthma by Modulating Yes-associated Protein,” Journal of Cellular and Molecular Medicine 24, no. 14 (2020): 8179–8193.

[79] F. Wei and Y. Hao, “TRIP6 accelerates the Proliferation and Migration of Fetal Airway Smooth Muscle Cells by Enhancing YAP Activation,” International Immunopharmacology 82 (2020): 106366.

[80] S. Zeng, J. Cui, Y. Zhang, Z. Zheng, J. Meng, and J. Du, “MicroRNA-15b-5p Inhibits Tumor Necrosis Factor Alpha-induced Proliferation, Migration, and Extracellular Matrix Production of Airway Smooth Muscle Cells via Targeting Yes-associated Protein 1,” Bioengineered 13, no. 3 (2022): 5396–5406.

[81] P. Fang, W. J. Deng, N. Fan, et al., “AMOTL2 restrains Transforming Growth Factor-beta1-induced Proliferation and Extracellular Matrix Deposition of Airway Smooth Muscle Cells via the Down-regulation of YAP1 Activation,” Environmental Toxicology 36, no. 11 (2021): 2225–2235.

[82] H. Wang, Y. Zhang, B. Zhong, et al., “Cysteine and Glycine-rich Protein 2 Retards Platelet-derived Growth Factor-BB-evoked Phenotypic Transition of Airway Smooth Muscle Cells by Decreasing YAP/TAZ Activity,” Cell Biochemistry and Function 42, no. 1 (2024): e3896.

[83] Y. Zhao, X. Zhang, G. Wang, et al., “LXA4 inhibits TGF-beta1-induced Airway Smooth Muscle Cells Proliferation and Migration by Suppressing the Smad/YAP Pathway,” International Immunopharmacology 118 (2023): 110144.

[84] A. H. Massoud, L. M. Charbonnier, D. Lopez, M. Pellegrini, W. Phipatanakul, and T. A. Chatila, “An Asthma-associated IL4R Variant Exacerbates Airway Inflammation by Promoting Conversion of Regulatory T Cells to TH17-Like Cells,” Nature Medicine 22, no. 9 (2016): 1013–1022.

[85] R. G. Luo, Y. F. Wu, H. W. Lu, et al., “Th2-skewed Peripheral T Helper Cells Drives B Cells in Allergic Bronchopulmonary Aspergillosis,” European Respiratory Journal 63, no. 5 (2024): 2400386.

[86] Y. Xie, P. W. Abel, T. B. Casale, and Y. Tu, “T(H)17 Cells and Corticosteroid Insensitivity in Severe Asthma,” Journal of Allergy and Clinical Immunology 149, no. 2 (2022): 467–479.

[87] J. Zhou, N. Zhang, W. Zhang, C. Lu, and F. Xu, “The YAP/HIF-1alpha/miR-182/EGR2 Axis Is Implicated in Asthma Severity Through the Control of Th17 Cell Differentiation,” Cell & Bioscience 11, no. 1 (2021): 84.

[88] H. Grasemann and F. Ratjen, “Cystic Fibrosis,” New England Journal of Medicine 389, no. 18 (2023): 1693–1707.

[89] S. Y. Graeber and M. A. Mall, “The Future of Cystic Fibrosis Treatment: From Disease Mechanisms to Novel Therapeutic Approaches,” Lancet 402, no. 10408 (2023): 1185–1198.

[90] J. Levring, D. S. Terry, Z. Kilic, G. Fitzgerald, S. C. Blanchard, and J. Chen, “CFTR Function, Pathology and Pharmacology at Single-molecule Resolution,” Nature 616, no. 7957 (2023): 606–614.

[91] M. Egan, T. Flotte, S. Afione, et al., “Defective Regulation of Outwardly Rectifying Cl-channels by Protein Kinase A Corrected by Insertion of CFTR,” Nature 358, no. 6387 (1992): 581–584.

[92] M. C. Quaresma, H. M. Botelho, I. Pankonien, et al., “Exploring YAP1-centered Networks Linking Dysfunctional CFTR to Epithelial-mesenchymal Transition,” Life Science Alliance 5, no. 9 (2022): e202101326.

[93] J. L. Simonin, C. Tomba, V. Mercier, et al., “Apical Dehydration Impairs the Cystic Fibrosis Airway Epithelium Barrier via a beta1-integrin/YAP1 Pathway,” Life Science Alliance 7, no. 4 (2024): e202302449.

[94] S. K. Rajan, V. Cottin, R. Dhar, et al., “Progressive Pulmonary Fibrosis: An Expert Group Consensus Statement,” European Respiratory Journal 61, no. 3 (2023): 2103187.

[95] T. Koudstaal, M. Funke-Chambour, M. Kreuter, P. L. Molyneaux, and M. S. Wijsenbeek, “Pulmonary Fibrosis: From Pathogenesis to Clinical Decision-making,” Trends in Molecular Medicine 29, no. 12 (2023): 1076–1087.

[96] P. W. Noble, C. E. Barkauskas, and D. Jiang, “Pulmonary Fibrosis: Patterns and Perpetrators,” Journal of Clinical Investigation 122, no. 8 (2012): 2756–2762.

[97] L. Richeldi, H. R. Collard, and M. G. Jones, “Idiopathic Pulmonary Fibrosis,” Lancet 389, no. 10082 (2017): 1941–1952.

[98] T. Zhang, X. He, L. Caldwell, et al., “NUAK1 promotes Organ Fibrosis via YAP and TGF-beta/SMAD Signaling,” Science Translational Medicine 14, no. 637 (2022): eaaz4028.

[99] A. J. Haak, E. Kostallari, D. Sicard, et al., “Selective YAP/TAZ Inhibition in Fibroblasts via Dopamine Receptor D1 Agonism Reverses Fibrosis,” Science Translational Medicine 11, no. 516 (2019): eaau6296.

[100] K. Zmajkovicova, K. Menyhart, Y. Bauer, et al., “The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated Through Inhibition of YAP/TAZ,” American Journal of Respiratory Cell and Molecular Biology 60, no. 5 (2019): 578–591.

[101] P. J. Barnes, “New Anti-inflammatory Targets for Chronic Obstructive Pulmonary Disease,” Nature Reviews Drug Discovery 12, no. 7 (2013): 543–559.

[102] S. P. Bhatt, A. Agusti, M. Bafadhel, et al., “Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 208, no. 10 (2023): 1026–1041.

[103] V. Laiman, Y. L. Lee, Y. W. Hou, et al., “Reduction of Emphysema Severity by Human Umbilical Cord-Derived Mesenchymal Stem Cells in Mice,” International Journal of Molecular Sciences 23, no. 16 (2022): 8906.

[104] F. J. Li, R. Surolia, H. Li, et al., “Low-dose Cadmium Exposure Induces Peribronchiolar Fibrosis Through Site-specific Phosphorylation of Vimentin,” American Journal of Physiology. Lung Cellular and Molecular Physiology 313, no. 1 (2017): L80–L91.

[105] V. N. Petrova and C. A. Russell, “The Evolution of Seasonal Influenza Viruses,” Nature Reviews Microbiology 16, no. 1 (2018): 60.

[106] J. S. Long, B. Mistry, S. M. Haslam, and W. S. Barclay, “Host and Viral Determinants of Influenza A Virus Species Specificity,” Nature Reviews Microbiology 17, no. 2 (2019): 67–81.

[107] T. Flerlage, D. F. Boyd, V. Meliopoulos, P. G. Thomas, and S. Schultz-Cherry, “Influenza Virus and SARS-CoV-2: Pathogenesis and Host Responses in the respiratory Tract,” Nature Reviews Microbiology 19, no. 7 (2021): 425–441.

[108] T. M. Uyeki, D. S. Hui, M. Zambon, D. E. Wentworth, and A. S. Monto, “Influenza,” Lancet 400, no. 10353 (2022): 693–706.

[109] B. Hu, H. Guo, P. Zhou, and Z. L. Shi, “Characteristics of SARS-CoV-2 and COVID-19,” Nature Reviews Microbiology 19, no. 3 (2021): 141–154.

[110] A. Sette and S. Crotty, “Adaptive Immunity to SARS-CoV-2 and COVID-19,” Cell 184, no. 4 (2021): 861–880.

[111] H. M Al-Kuraishy, A. I Al-Gareeb, H. M. Saad, and G. E. Batiha, “Hippo-YAP Signaling and SARS-CoV-2 Infection: A New Mechanistic Pathway,” Cell Stress & Chaperones 28, no. 2 (2023): 121–123.

[112] H. M Al-Kuraishy, G. E. Batiha, H. Faidah, A. I Al-Gareeb, H. M. Saad, and J. Simal-Gandara, “Pirfenidone and post-Covid-19 Pulmonary Fibrosis: Invoked Again for Realistic Goals,” Inflammopharmacology 30, no. 6 (2022): 2017–2026.

[113] Q. Zhang, X. Zhang, X. Lei, et al., “Influenza A Virus NS1 Protein Hijacks YAP/TAZ to Suppress TLR3-mediated Innate Immune Response,” PLoS Pathogens 18, no. 5 (2022): e1010505.

[114] R. Li, J. Shao, Y. J. Jin, et al., “Endothelial FAT1 Inhibits Angiogenesis by Controlling YAP/TAZ Protein Degradation via E3 Ligase MIB2,” Nature Communications 14, no. 1 (2023): 1980.

[115] Y. Wang, G. Hu, F. Liu, et al., “Deletion of Yes-associated Protein (YAP) Specifically in Cardiac and Vascular Smooth Muscle Cells Reveals a Crucial Role for YAP in Mouse Cardiovascular Development,” Circulation Research 114, no. 6 (2014): 957–965.

[116] N. F. Ruopp and B. A. Cockrill, “Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review,” Jama 327, no. 14 (2022): 1379–1391.

[117] A. Mocumbi, M. Humbert, A. Saxena, et al., “Pulmonary Hypertension,” Nature Reviews Disease Primers 10, no. 1 (2024): 1.

[118] B. A. Maron and N. Galie, “Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review,” JAMA Cardiology 1, no. 9 (2016): 1056–1065.

[119] K. Jandl, N. Radic, K. Zeder, G. Kovacs, and G. Kwapiszewska, “Pulmonary Vascular Fibrosis in Pulmonary Hypertension—The Role of the Extracellular Matrix as a Therapeutic Target,” Pharmacology & Therapeutics 247 (2023): 108438.

[120] P. B. Dieffenbach, C. Mallarino Haeger, R. Rehman, et al., “A Novel Protective Role for Matrix Metalloproteinase-8 in the Pulmonary Vasculature,” American Journal of Respiratory and Critical Care Medicine 204, no. 12 (2021): 1433–1451.

[121] T. V. Kudryashova, D. A. Goncharov, A. Pena, et al., “HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension,” American Journal of Respiratory and Critical Care Medicine 194, no. 7 (2016): 866–877.

[122] J. Liu, J. Wang, Y. Liu, et al., “Liquid-Liquid Phase Separation of DDR1 Counteracts the Hippo Pathway to Orchestrate Arterial Stiffening,” Circulation Research 132, no. 1 (2023): 87–105.

[123] T. Bertero, W. M. Oldham, K. A. Cottrill, et al., “Vascular Stiffness Mechanoactivates YAP/TAZ-dependent Glutaminolysis to Drive Pulmonary Hypertension,” Journal of Clinical Investigation 126, no. 9 (2016): 3313–3335.

[124] P. Libby, “The Changing Landscape of Atherosclerosis,” Nature 592, no. 7855 (2021): 524–533.

[125] J. L. M. Bjorkegren and A. J. Lusis, “Atherosclerosis: Recent Developments,” Cell 185, no. 10 (2022): 1630–1645.

[126] P. Libby, J. E. Buring, L. Badimon, et al., “Atherosclerosis,” Nature Reviews Disease Primers 5, no. 1 (2019): 56.

[127] L. Wang, J. Y. Luo, B. Li, et al., “Integrin-YAP/TAZ-JNK Cascade Mediates Atheroprotective Effect of Unidirectional Shear Flow,” Nature 540, no. 7634 (2016): 579–582.

[128] K. C. Wang, Y. T. Yeh, P. Nguyen, et al., “Flow-dependent YAP/TAZ Activities Regulate Endothelial Phenotypes and Atherosclerosis,” Proceeding of the National Academy of Sciences in the United States of America 113, no. 41 (2016): 11525–11530.

[129] S. Xu, M. Koroleva, M. Yin, and Z. G. Jin, “Atheroprotective Laminar Flow Inhibits Hippo Pathway Effector YAP in Endothelial Cells,” Translational Research 176 (2016): 18–28. e12.

[130] M. C. Jiang, H. Y. Ding, Y. H. Huang, et al., “Thioridazine Protects Against Disturbed Flow-induced Atherosclerosis by Inhibiting RhoA/YAP-mediated Endothelial Inflammation,” Acta Pharmacologica Sinica 44, no. 10 (2023): 1977–1988.

[131] J. Liu, C. Zhao, X. Xiao, et al., “Endothelial Discoidin Domain Receptor 1 Senses Flow to Modulate YAP Activation,” Nature Communications 14, no. 1 (2023): 6457.

[132] B. Li, J. He, H. Lv, et al., “c-Abl Regulates YAPY357 Phosphorylation to Activate Endothelial Atherogenic Responses to Disturbed Flow,” Journal of Clinical Investigation 129, no. 3 (2019): 1167–1179.

[133] M. Jia, Q. Li, J. Guo, et al., “Deletion of BACH1 Attenuates Atherosclerosis by Reducing Endothelial Inflammation,” Circulation Research 130, no. 7 (2022): 1038–1055.

[134] M. D. Samsky, D. A. Morrow, A. G. Proudfoot, J. S. Hochman, H. Thiele, and S. V. Rao, “Cardiogenic Shock after Acute Myocardial Infarction: A Review,” Jama 326, no. 18 (2021): 1840–1850.

[135] G. W. Reed, J. E. Rossi, and C. P. Cannon, “Acute Myocardial Infarction,” Lancet 389, no. 10065 (2017): 197–210.

[136] J. L. Anderson and D. A. Morrow, “Acute Myocardial Infarction,” New England Journal of Medicine 376, no. 21 (2017): 2053–2064.

[137] J. Sadoshima, “YAP Promotes Infarct Resolution by Stimulating Intercellular Signaling,” Circulation Research 129, no. 8 (2021): 798–800.

[138] D. P. Del Re, “Beyond the Cardiomyocyte: Consideration of HIPPO Pathway Cell-Type Specificity,” Circulation Research 123, no. 1 (2018): 30–32.

[139] G. Garoffolo, M. Casaburo, F. Amadeo, et al., “Reduction of Cardiac Fibrosis by Interference with YAP-Dependent Transactivation,” Circulation Research 131, no. 3 (2022): 239–257.

[140] Z. Lin, A. von Gise, P. Zhou, et al., “Cardiac-specific YAP Activation Improves Cardiac Function and Survival in an Experimental Murine MI Model,” Circulation Research 115, no. 3 (2014): 354–363.

[141] Y. Morikawa, T. Heallen, J. Leach, Y. Xiao, and J. F. Martin, “Dystrophin-glycoprotein Complex Sequesters Yap to Inhibit Cardiomyocyte Proliferation,” Nature 547, no. 7662 (2017): 227–231.

[142] M. M. Mia, D. M. Cibi, S. A. B. Abdul Ghani, et al., “YAP/TAZ Deficiency Reprograms Macrophage Phenotype and Improves Infarct Healing and Cardiac Function After Myocardial Infarction,” PLoS Biology 18, no. 12 (2020): e3000941.

[143] A. Aharonov, A. Shakked, K. B. Umansky, et al., “ERBB2 drives YAP Activation and EMT-Like Processes During Cardiac Regeneration,” Nature Cell Biology 22, no. 11 (2020): 1346–1356.

[144] D. Zhang, J. Ning, T. Ramprasath, et al., “Kynurenine Promotes Neonatal Heart Regeneration by Stimulating Cardiomyocyte Proliferation and Cardiac Angiogenesis,” Nature Communications 13, no. 1 (2022): 6371.

[145] X. Wang, T. Ha, L. Liu, et al., “TLR3 Mediates Repair and Regeneration of Damaged Neonatal Heart Through Glycolysis Dependent YAP1 Regulated miR-152 Expression,” Cell Death and Differentiation 25, no. 5 (2018): 966–982.

[146] J. Li, E. Gao, A. Vite, et al., “Alpha-catenins Control Cardiomyocyte Proliferation by Regulating Yap Activity,” Circulation Research 116, no. 1 (2015): 70–79.

[147] Y. Li, J. Feng, S. Song, et al., “gp130 Controls Cardiomyocyte Proliferation and Heart Regeneration,” Circulation 142, no. 10 (2020): 967–982.

[148] C. J. Boogerd, I. Perini, E. Kyriakopoulou, et al., “Cardiomyocyte Proliferation Is Suppressed by ARID1A-mediated YAP Inhibition During Cardiac Maturation,” Nature Communications 14, no. 1 (2023): 4716.

[149] V. Ramjee, D. Li, L. J. Manderfield, et al., “Epicardial YAP/TAZ Orchestrate an Immunosuppressive Response Following Myocardial Infarction,” Journal of Clinical Investigation 127, no. 3 (2017): 899–911.

[150] T. Matsuda, P. Zhai, S. Sciarretta, et al., “NF2 Activates Hippo Signaling and Promotes Ischemia/Reperfusion Injury in the Heart,” Circulation Research 119, no. 5 (2016): 596–606.

[151] D. Shao, P. Zhai, D. P. Del Re, et al., “A Functional Interaction Between Hippo-YAP Signalling and FoxO1 Mediates the Oxidative Stress Response,” Nature Communications 5 (2014): 3315.

[152] Y. Yang, D. P. Del Re, N. Nakano, et al., “miR-206 Mediates YAP-Induced Cardiac Hypertrophy and Survival,” Circulation Research 117, no. 10 (2015): 891–904.

[153] M. Qiu, W. Yan, and M. Liu, “YAP Facilitates NEDD4L-Mediated Ubiquitination and Degradation of ACSL4 to Alleviate Ferroptosis in Myocardial Ischemia-Reperfusion Injury,” Canadian Journal of Cardiology 39, no. 11 (2023): 1712–1727.

[154] G. Zhong, S. Su, J. Li, et al., “Activation of Piezo1 Promotes Osteogenic Differentiation of Aortic Valve Interstitial Cell Through YAP-dependent Glutaminolysis,” Science Advances 9, no. 22 (2023): eadg0478.

[155] Z. D. Pang, X. Sun, R. Y. Bai, et al., “YAP-galectin-3 Signaling Mediates Endothelial Dysfunction in Angiotensin II-induced Hypertension in Mice,” Cellular and Molecular Life Sciences 80, no. 2 (2023): 38.

[156] S. Ikeda, W. Mizushima, S. Sciarretta, et al., “Hippo Deficiency Leads to Cardiac Dysfunction Accompanied by Cardiomyocyte Dedifferentiation during Pressure Overload,” Circulation Research 124, no. 2 (2019): 292–305.

[157] J. Wang, S. Liu, T. Heallen, and J. F. Martin, “The Hippo Pathway in the Heart: Pivotal Roles in Development, Disease, and Regeneration,” Nature Reviews Cardiology 15, no. 11 (2018): 672–684.

[158] F. Biagioni, O. Croci, S. Sberna, et al., “Decoding YAP Dependent Transcription in the Liver,” Nucleic Acids Research 50, no. 14 (2022): 7959–7971.

[159] W. Li, L. Yang, Q. He, et al., “A Homeostatic Arid1a-Dependent Permissive Chromatin State Licenses Hepatocyte Responsiveness to Liver-Injury-Associated YAP Signaling,” Cell Stem Cell 25, no. 1 (2019): 54–68. e55.

[160] K. Liu, L. Wehling, S. Wan, et al., “Dynamic YAP Expression in the Non-parenchymal Liver Cell Compartment Controls Heterologous Cell Communication,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 115.

[161] H. Hirao, K. Nakamura, and J. W. Kupiec-Weglinski, “Liver Ischaemia-reperfusion Injury: A New Understanding of the Role of Innate Immunity,” Nature Reviews Gastroenterology & Hepatology 19, no. 4 (2022): 239–256.

[162] C. Peralta, M. B Jimenez-Castro, and J. Gracia-Sancho, “Hepatic Ischemia and Reperfusion Injury: Effects on the Liver Sinusoidal Milieu,” Journal of Hepatology 59, no. 5 (2013): 1094–1106.

[163] D. A. Parks and D. N. Granger, “Ischemia-reperfusion Injury: A Radical View,” Hepatology 8, no. 3 (1988): 680–682.

[164] J. Zhou, M. Hu, M. He, et al., “TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting against Hepatic Ischemia/Reperfusion Injury,” Hepatology 74, no. 4 (2021): 2133–2153.

[165] J. Rao, F. Cheng, H. Zhou, et al., “Nogo-B Is a Key Mediator of Hepatic Ischemia and Reperfusion Injury,” Redox Biology 37 (2020): 101745.

[166] Y. Liu, T. Lu, C. Zhang, et al., “Activation of YAP Attenuates Hepatic Damage and Fibrosis in Liver Ischemia-reperfusion Injury,” Journal of Hepatology 71, no. 4 (2019): 719–730.

[167] S. Zhang, Z. Sun, Z. Chen, et al., “Endothelial YAP/TEAD1-CXCL17 Signaling Recruits Myeloid-derived Suppressor Cells Against Liver Ischemia-reperfusion Injury,” Hepatology 81, no. 3 (2024): 888–902.

[168] Z. Yuan, L. Ye, X. Feng, et al., “YAP-Dependent Induction of CD47-Enriched Extracellular Vesicles Inhibits Dendritic Cell Activation and Ameliorates Hepatic Ischemia-Reperfusion Injury,” Oxidative Medicine and Cellular Longevity 2021 (2021): 6617345.

[169] W. J. Jeng, G. V. Papatheodoridis, A. S. F. Lok, and B. Hepatitis, Lancet 401, no. 10381 (2023): 1039–1052.

[170] R. S. Khan, P. F. Lalor, M. Thursz, and P. N. Newsome, “The Role of Neutrophils in Alcohol-related hepatitis,” Journal of Hepatology 79, no. 4 (2023): 1037–1048.

[171] G. Mieli-Vergani and D. Vergani, “Autoimmune hepatitis,” Nature Reviews Gastroenterology & Hepatology 8, no. 6 (2011): 320–329.

[172] A. Vogel, T. Meyer, G. Sapisochin, R. Salem, and A. Saborowski, “Hepatocellular Carcinoma,” Lancet 400, no. 10360 (2022): 1345–1362.

[173] J. D. Yang, P. Hainaut, G. J. Gores, A. Amadou, A. Plymoth, and L. R. Roberts, “A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management,” Nature Reviews Gastroenterology & Hepatology 16, no. 10 (2019): 589–604.

[174] M. Bou Saleh, A. Louvet, L. C Ntandja-Wandji, et al., “Loss of Hepatocyte Identity Following Aberrant YAP Activation: A Key Mechanism in Alcoholic hepatitis,” Journal of Hepatology 75, no. 4 (2021): 912–923.

[175] P. Kusumanchi, T. Liang, T. Zhang, et al., “Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling,” Hepatology 74, no. 3 (2021): 1234–1250.

[176] Y. Hao, D. Feng, H. Ye, and W. Liao, “Nobiletin Alleviated Epithelial-Mesenchymal Transition of Hepatocytes in Liver Fibrosis Based on Autophagy-Hippo/YAP Pathway,” Molecular Nutrition & Food Research 68, no. 3 (2024): e2300529.

[177] Y. Aylon, A. Gershoni, R. Rotkopf, et al., “The LATS2 Tumor Suppressor Inhibits SREBP and Suppresses Hepatic Cholesterol Accumulation,” Genes & Development 30, no. 7 (2016): 786–797.

[178] C. Priest, R. T. Nagari, L. Bideyan, et al., “Brap Regulates Liver Morphology and Hepatocyte Turnover via Modulation of the Hippo Pathway,” Proceeding of the National Academy of Sciences in the United States of America 119, no. 18 (2022): e2201859119.

[179] M. Mooring, B. H. Fowl, S. Z. C. Lum, et al., “Hepatocyte Stress Increases Expression of Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis,” Hepatology 71, no. 5 (2020): 1813–1830.

[180] C. Li, Y. Jin, S. Wei, et al., “Hippo Signaling Controls NLR Family Pyrin Domain Containing 3 Activation and Governs Immunoregulation of Mesenchymal Stem Cells in Mouse Liver Injury,” Hepatology 70, no. 5 (2019): 1714–1731.

[181] T. Yang, X. Qu, X. Wang, et al., “The Macrophage STING-YAP Axis Controls Hepatic Steatosis by Promoting the Autophagic Degradation of Lipid Droplets,” Hepatology 80, no. 5 (2023): 1169–1183.

[182] S. Alsamman, S. A. Christenson, A. Yu, et al., “Targeting Acid Ceramidase Inhibits YAP/TAZ Signaling to Reduce Fibrosis in Mice,” Science Translational Medicine 12, no. 557 (2020): eaay8798.

[183] I. Mederacke, A. Filliol, S. Affo, et al., “The Purinergic P2Y14 Receptor Links Hepatocyte Death to Hepatic Stellate Cell Activation and Fibrogenesis in the Liver,” Science Translational Medicine 14, no. 639 (2022): eabe5795.

[184] K. Song, H. Kwon, C. Han, et al., “Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis,” Hepatology 72, no. 1 (2020): 72–87.

[185] J. Torres, S. Mehandru, and J. F. Colombel, “Peyrin-Biroulet L,” Lancet 389, no. 10080 (2017): 1741–1755.

[186] G. Roda, S. Chien Ng, P. G. Kotze, et al., “Crohn’s Disease,” Nature Reviews Disease Primers 6, no. 1 (2020): 22.

[187] C. Le Berre, S. Honap, and L. Peyrin-Biroulet, “Ulcerative Colitis,” Lancet 402, no. 10401 (2023): 571–584.

[188] S. Thorsteinsdottir, T. Gudjonsson, O. H. Nielsen, B. Vainer, and J. B. Seidelin, “Pathogenesis and Biomarkers of Carcinogenesis in Ulcerative Colitis,” Nature Reviews Gastroenterology & Hepatology 8, no. 7 (2011): 395–404.

[189] L. Liu, Y. Wang, S. Yu, et al., “Transforming Growth Factor Beta Promotes Inflammation and Tumorigenesis in Smad4-Deficient Intestinal Epithelium in a YAP-Dependent Manner,” Advanced Science (Weinh) 10, no. 23 (2023): e2300708.

[190] K. Taniguchi, L. W. Wu, S. I. Grivennikov, et al., “A gp130-Src-YAP Module Links Inflammation to Epithelial Regeneration,” Nature 519, no. 7541 (2015): 57–62.

[191] H. Zhu, J. Lu, M. Fu, et al., “YAP Represses Intestinal Inflammation Through Epigenetic Silencing of JMJD3,” Clinical Epigenetics 16, no. 1 (2024): 14.

[192] Y. Liu, Y. Ji, R. Jiang, et al., “Reduced Smooth Muscle-fibroblasts Transformation Potentially Decreases Intestinal Wound Healing and Colitis-associated Cancer in Ageing Mice,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 294.

[193] M. Yu, Y. Luo, Z. Cong, Y. Mu, Y. Qiu, and M. Zhong, “MicroRNA-590-5p Inhibits Intestinal Inflammation by Targeting YAP,” Journal of Crohn’s and Colitis 12, no. 8 (2018): 993–1004.

[194] F. Deng, Z. Wu, F. Zou, S. Wang, and X. Wang, “The Hippo-YAP/TAZ Signaling Pathway in Intestinal Self-Renewal and Regeneration after Injury,” Frontiers in Cell and Developmental Biology 10 (2022): 894737.

[195] D. Chakravarti, R. Lee, A. S. Multani, et al., “Telomere Dysfunction Instigates Inflammation in Inflammatory Bowel Disease,” Proceeding of the National Academy of Sciences in the United States of America 118, no. 29 (2021): e2024853118.

[196] S. He, P. Lei, W. Kang, et al., “Stiffness Restricts the Stemness of the Intestinal Stem Cells and Skews Their Differentiation toward Goblet Cells,” Gastroenterology 164, no. 7 (2023): 1137–1151. e1115.

[197] X. Zhou, W. Li, S. Wang, et al., “YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis,” Cell reports 27, no. 4 (2019): 1176–1189. e1175.

[198] W. Ou, W. Xu, F. Liu, et al., “Increased Expression of Yes-associated Protein/YAP and Transcriptional Coactivator With PDZ-binding Motif/TAZ Activates Intestinal Fibroblasts to Promote Intestinal Obstruction in Crohn’s disease,” EBioMedicine 69 (2021): 103452.

[199] P. Zhang, T. Wang, D. Zhang, et al., “Exploration of MST1-Mediated Secondary Brain Injury Induced by Intracerebral Hemorrhage in Rats via Hippo Signaling Pathway,” Translational Stroke Research 10, no. 6 (2019): 729–743.

[200] Y. Yang, J. Ren, Y. Sun, et al., “A connexin43/YAP Axis Regulates Astroglial-mesenchymal Transition in Hemoglobin Induced Astrocyte Activation,” Cell Death and Differentiation 25, no. 10 (2018): 1870–1884.

[201] Z. Huang, Y. Wang, G. Hu, J. Zhou, L. Mei, and W. C. Xiong, “YAP Is a Critical Inducer of SOCS3, Preventing Reactive Astrogliosis,” Cerebral Cortex 26, no. 5 (2016): 2299–2310.

[202] W. Li, P. Xu, L. Kong, et al., “Elabela-APJ Axis Mediates Angiogenesis via YAP/TAZ Pathway in Cerebral Ischemia/Reperfusion Injury,” Translational Research 257 (2023): 78–92.

[203] A. Vivante, “Genetics of Chronic Kidney Disease,” New England Journal of Medicine 391, no. 7 (2024): 627–639.

[204] P. Drawz and M. Rahman, “Chronic Kidney Disease,” Annals of Internal Medicine 162, no. 11 (2015): ITC1–16.

[205] J. A. Kellum, P. Romagnani, G. Ashuntantang, C. Ronco, A. Zarbock, and H. J. Anders, “Acute Kidney Injury,” Nature Reviews Disease Primers 7, no. 1 (2021): 52.

[206] C. Ronco, R. Bellomo, and J. A. Kellum, “Acute Kidney Injury,” Lancet 394, no. 10212 (2019): 1949–1964.

[207] T. T. Wang, L. L. Wu, J. Wu, et al., “14-3-3zeta inhibits Maladaptive Repair in Renal Tubules by Regulating YAP and Reduces Renal Interstitial Fibrosis,” Acta Pharmacologica Sinica 44, no. 2 (2023): 381–392.

[208] D. Xu, P. P. Chen, P. Q. Zheng, et al., “KLF4 initiates Sustained YAP Activation to Promote Renal Fibrosis in Mice After Ischemia-reperfusion Kidney Injury,” Acta Pharmacologica Sinica 42, no. 3 (2021): 436–450.

[209] J. Chen, H. You, Y. Li, Y. Xu, Q. He, and R. C. Harris, “EGF Receptor-Dependent YAP Activation Is Important for Renal Recovery From AKI,” Journal of the American Society of Nephrology 29, no. 9 (2018): 2372–2385.

[210] M. M. Rinschen, F. Grahammer, A. K. Hoppe, et al., “YAP-mediated Mechanotransduction Determines the Podocyte’s Response to Damage,” Science Signaling 10, no. 474 (2017): eaaf8165.

[211] Y. Liu, Y. Wang, C. Xu, et al., “Activation of the YAP/KLF5 Transcriptional Cascade in Renal Tubular Cells Aggravates Kidney Injury,” Molecular Therapy 32, no. 5 (2024): 1526–1539.

[212] J. Xu, P. X. Li, J. Wu, et al., “Involvement of the Hippo Pathway in Regeneration and Fibrogenesis After Ischaemic Acute Kidney Injury: YAP Is the Key Effector,” Clinical Science (London, England: 1979) 130, no. 5 (2016): 349–363.

[213] D. J. Hunter and S. Bierma-Zeinstra, “Osteoarthritis,” Lancet 393, no. 10182 (2019): 1745–1759.

[214] J. Martel-Pelletier, A. J. Barr, F. M. Cicuttini, et al., “Osteoarthritis,” Nature Reviews Disease Primers 2 (2016): 16072.

[215] A. Bottini, D. J. Wu, R. Ai, et al., “PTPN14 phosphatase and YAP Promote TGFbeta Signalling in Rheumatoid Synoviocytes,” Annals of the Rheumatic Diseases 78, no. 5 (2019): 600–609.

[216] A. S. Thorup, D. Strachan, S. Caxaria, et al., “ROR2 blockade as a Therapy for Osteoarthritis,” Science Translational Medicine 12, no. 561 (2020): eaax3063.

[217] Y. Deng, J. Lu, W. Li, et al., “Reciprocal Inhibition of YAP/TAZ and NF-kappaB Regulates Osteoarthritic Cartilage Degradation,” Nature Communications 9, no. 1 (2018): 4564.

[218] T. van der Poll, M. Shankar-Hari, and W. J. Wiersinga, “The Immunology of Sepsis,” Immunity 54, no. 11 (2021): 2450–2464.

[219] M. Cecconi, L. Evans, M. Levy, and A. Rhodes, “Sepsis and Septic Shock,” Lancet 392, no. 10141 (2018): 75–87.

[220] R. S. Hotchkiss, L. L. Moldawer, S. M. Opal, K. Reinhart, I. R. Turnbull, and J. L. Vincent, “Sepsis and Septic Shock,” Nature Reviews Disease Primers 2 (2016): 16045.

[221] K. Yang, M. Fan, X. Wang, et al., “Lactate Promotes Macrophage HMGB1 Lactylation, Acetylation, and Exosomal Release in Polymicrobial Sepsis,” Cell Death and Differentiation 29, no. 1 (2022): 133–146.

[222] S. Chatterjee, K. Khunti, and M. J. Davies, “Type 2 Diabetes,” Lancet 389, no. 10085 (2017): 2239–2251.

[223] F. H El-Khatib, C. Balliro, M. A. Hillard, et al., “Home Use of a Bihormonal Bionic Pancreas versus Insulin Pump Therapy in Adults With Type 1 Diabetes: A Multicentre Randomised Crossover Trial,” Lancet 389, no. 10067 (2017): 369–380.

[224] M. L. Chao, S. Luo, C. Zhang, et al., “S-nitrosylation-mediated Coupling of G-protein Alpha-2 With CXCR5 Induces Hippo/YAP-dependent Diabetes-accelerated Atherosclerosis,” Nature Communications 12, no. 1 (2021): 4452.

[225] L. Kang, J. Yi, C. W. Lau, et al., “AMPK-Dependent YAP Inhibition Mediates the Protective Effect of Metformin Against Obesity-Associated Endothelial Dysfunction and Inflammation,” Antioxidants (Basel) 12, no. 9 (2023): 1681.

[226] J. Chen and R. C. Harris, “Interaction of the EGF Receptor and the Hippo Pathway in the Diabetic Kidney,” Journal of the American Society of Nephrology 27, no. 6 (2016): 1689–1700.

[227] J. Chen, X. Wang, Q. He, H. C. Yang, A. B. Fogo, and R. C. Harris, “Inhibition of Transcriptional Coactivator YAP Impairs the Expression and Function of Transcription Factor WT1 in Diabetic Podocyte Injury,” Kidney International 105, no. 6 (2024): 1200–1211.

[228] S. Choi, S. P. Hong, J. H. Bae, et al., “Hyperactivation of YAP/TAZ Drives Alterations in Mesangial Cells Through Stabilization of N-Myc in Diabetic Nephropathy,” Journal of the American Society of Nephrology 34, no. 5 (2023): 809–828.

[229] M. J. Oudhoff, F. Antignano, A. L. Chenery, et al., “Intestinal Epithelial Cell-Intrinsic Deletion of Setd7 Identifies Role for Developmental Pathways in Immunity to Helminth Infection,” PLoS Pathogens 12, no. 9 (2016): e1005876.

[230] S. C. Lin, H. C. Lee, P. C. Hou, J. L. Fu, M. H. Wu, and S. J. Tsai, “Targeting Hypoxia-mediated YAP1 Nuclear Translocation Ameliorates Pathogenesis of Endometriosis Without Compromising Maternal Fertility,” Journal of Pathology 242, no. 4 (2017): 476–487.

[231] L. Wang, S. Wang, Y. Shi, et al., “YAP and TAZ Protect Against White Adipocyte Cell Death During Obesity,” Nature Communications 11, no. 1 (2020): 5455.

[232] W. Pan, L. Yang, J. Li, et al., “Traumatic Occlusion Aggravates Bone Loss During Periodontitis and Activates Hippo-YAP Pathway,” Journal of Clinical Periodontology 46, no. 4 (2019): 438–447.

[233] D. D. Shao, W. Xue, E. B. Krall, et al., “KRAS and YAP1 Converge to Regulate EMT and Tumor Survival,” Cell 158, no. 1 (2014): 171–184.

[234] J. D. Pearson, K. Huang, M. Pacal, et al., “Binary Pan-cancer Classes With Distinct Vulnerabilities Defined by Pro-or Anti-cancer YAP/TEAD Activity,” Cancer Cell 39, no. 8 (2021): 1115–1134. e1112.

[235] I. Bado and X. H. Zhang, “Senesce to Survive: YAP-Mediated Dormancy Escapes EGFR/MEK Inhibition,” Cancer Cell 37, no. 1 (2020): 1–2.

[236] J. A. Ajani, Y. Xu, L. Huo, et al., “YAP1 mediates Gastric Adenocarcinoma Peritoneal Metastases That Are Attenuated by YAP1 Inhibition,” Gut 70, no. 1 (2021): 55–66.

[237] F. Zanconato, G. Battilana, M. Forcato, et al., “Transcriptional Addiction in Cancer Cells Is Mediated by YAP/TAZ Through BRD4,” Nature Medicine 24, no. 10 (2018): 1599–1610.

[238] F. Zanconato, M. Forcato, G. Battilana, et al., “Genome-wide Association Between YAP/TAZ/TEAD and AP-1 at Enhancers Drives Oncogenic Growth,” Nature Cell Biology 17, no. 9 (2015): 1218–1227.

[239] C. Peng, Y. Zhu, W. Zhang, et al., “Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation,” Molecular Cell 68, no. 3 (2017): 591–604. e595.

[240] D. E. Pefani, D. Pankova, A. G. Abraham, et al., “TGF-beta Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation,” Molecular Cell 63, no. 1 (2016): 156–166.

[241] I. Marigo, R. Trovato, F. Hofer, et al., “Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages,” Cancer Discovery 10, no. 11 (2020): 1758–1773.

[242] D. Chen, Y. Sun, Y. Wei, et al., “LIFR Is a Breast Cancer Metastasis Suppressor Upstream of the Hippo-YAP Pathway and a Prognostic Marker,” Nature Medicine 18, no. 10 (2012): 1511–1517.

[243] X. Ni, J. Tao, J. Barbi, et al., “YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity,” Cancer Discovery 8, no. 8 (2018): 1026–1043.

[244] F. Li, Y. Xu, B. Liu, et al., “YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer—Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer,” Clinical Cancer Research 25, no. 7 (2019): 2264–2277.

[245] Z. Li, P. Razavi, Q. Li, et al., “Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway,” Cancer Cell 34, no. 6 (2018): 893–905. e898.

[246] K. Du, R. Maeso-Diaz, S. H. Oh, et al., “Targeting YAP-mediated HSC Death Susceptibility and Senescence for Treatment of Liver Fibrosis,” Hepatology 77, no. 6 (2023): 1998–2015.

[247] Y. Gu, T. Xu, Y. Fang, et al., “CBX4 counteracts Cellular Senescence to Desensitize Gastric Cancer Cells to Chemotherapy by Inducing YAP1 SUMOylation,” Drug Resistance Updates 77 (2024): 101136.

[248] A. Claude-Taupin, P. Isnard, A. Bagattin, et al., “The AMPK-Sirtuin 1-YAP Axis Is Regulated by Fluid Flow Intensity and Controls Autophagy Flux in Kidney Epithelial Cells,” Nature Communications 14, no. 1 (2023): 8056.

[249] S. Ikeda, J. Nah, A. Shirakabe, et al., “YAP Plays a Crucial Role in the Development of Cardiomyopathy in Lysosomal Storage Diseases,” Journal of Clinical Investigation 131, no. 5 (2021): e143173.

[250] T. P. Neufeld, “Hippo Signaling: Autophagy Waits in the Wings,” Developmental Cell 52, no. 5 (2020): 544–545.

[251] G. Seo, C. Yu, H. Han, et al., “The Hippo Pathway Noncanonically Drives Autophagy and Cell Survival in Response to Energy Stress,” Molecular Cell 83, no. 17 (2023): 3155–3170. e3158.

[252] X. Wang, A. Freire Valls, G. Schermann, et al., “YAP/TAZ Orchestrate VEGF Signaling During Developmental Angiogenesis,” Developmental Cell 42, no. 5 (2017): 462–478. e467.

[253] A. L. Elaimy and A. M. Mercurio, “Convergence of VEGF and YAP/TAZ Signaling: Implications for Angiogenesis and Cancer Biology,” Science Signaling 11, no. 552 (2018): eaau1165.

[254] C. H. Hung, S. Y. Wu, C. D. Yao, et al., “Defective N-glycosylation of IL6 Induces Metastasis and Tyrosine Kinase Inhibitor Resistance in Lung Cancer,” Nature Communications 15, no. 1 (2024): 7885.

[255] E. Stampouloglou, N. Cheng, A. Federico, et al., “Yap Suppresses T-cell Function and Infiltration in the Tumor Microenvironment,” PLos Biology 18, no. 1 (2020): e3000591.

[256] A. Lebid, L. Chung, D. M. Pardoll, and F. Pan, “YAP Attenuates CD8 T Cell-Mediated Anti-tumor Response,” Frontiers in Immunology 11 (2020): 580.

[257] D. Matthaios, M. Tolia, D. Mauri, K. Kamposioras, and M. Karamouzis, “YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango,” Biomedicines 9, no. 12 (2021): 1949.

[258] J. Bai, M. Yan, Y. Xu, et al., “YAP Enhances Mitochondrial OXPHOS in Tumor-infiltrating Treg Through Upregulating Lars2 on Stiff Matrix,” Journal for ImmunoTherapy of Cancer 12, no. 11 (2024): e010463.

[259] Y. Fan, Y. Gao, J. Rao, K. Wang, F. Zhang, and C. Zhang, “YAP-1 Promotes Tregs Differentiation in Hepatocellular Carcinoma by Enhancing TGFBR2 Transcription,” Cellular Physiology and Biochemistry 41, no. 3 (2017): 1189–1198.

[260] J. H. Koo and K. L. Guan, “Interplay Between YAP/TAZ and Metabolism,” Cell Metabolism 28, no. 2 (2018): 196–206.

[261] K. H. Wrighton, “Metabolism: YAP and TAZ Under Metabolic Control,” Nature Reviews Molecular Cell Biology 15, no. 5 (2014): 296.

[262] S. M. White, M. L. Avantaggiati, I. Nemazanyy, et al., “YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells,” Developmental Cell 49, no. 3 (2019): 425–443. e429.

[263] M. Lv, Y. Gong, X. Liu, et al., “CDK7-YAP-LDHD Axis Promotes D-lactate Elimination and Ferroptosis Defense to Support Cancer Stem Cell-Like Properties,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 302.

[264] X. Zhang, A. Abdelrahman, B. Vollmar, and D. Zechner, “The Ambivalent Function of YAP in Apoptosis and Cancer,” International Journal of Molecular Sciences 19, no. 12 (2018): 3770.

[265] Q. Wu, J. Guo, Y. Liu, et al., “YAP Drives Fate Conversion and Chemoresistance of Small Cell Lung Cancer,” Science Advances 7, no. 40 (2021): eabg1850.

[266] A. L. Elaimy, J. J. Amante, L. J. Zhu, et al., “The VEGF Receptor Neuropilin 2 Promotes Homologous Recombination by Stimulating YAP/TAZ-mediated Rad51 Expression,” Proceeding of the National Academy of Sciences in the United States of America 116, no. 28 (2019): 14174–14180.

[267] F. Zanconato, M. Cordenonsi, and S. Piccolo, “YAP/TAZ at the Roots of Cancer,” Cancer Cell 29, no. 6 (2016): 783–803.

[268] Y. Shen, X. Wang, Y. Liu, et al., “STAT3-YAP/TAZ Signaling in Endothelial Cells Promotes Tumor Angiogenesis,” Science Signaling 14, no. 712 (2021): eabj8393.

[269] H. Croizer, R. Mhaidly, Y. Kieffer, et al., “Deciphering the Spatial Landscape and Plasticity of Immunosuppressive Fibroblasts in Breast Cancer,” Nature Communications 15, no. 1 (2024): 2806.

[270] J. Barbazan, C. Perez-Gonzalez, M. Gomez-Gonzalez, et al., “Cancer-associated Fibroblasts Actively Compress Cancer Cells and Modulate Mechanotransduction,” Nature Communications 14, no. 1 (2023): 6966.

[271] W. Chen, W. Peng, R. Wang, et al., “Exosome-derived tRNA Fragments tRF-GluCTC-0005 Promotes Pancreatic Cancer Liver Metastasis by Activating Hepatic Stellate Cells,” Cell Death & Disease 15, no. 1 (2024): 102.

[272] W. Yu, C. Zhang, Y. Wang, et al., “YAP 5-methylcytosine Modification Increases Its mRNA Stability and Promotes the Transcription of Exosome Secretion-related Genes in Lung Adenocarcinoma,” Cancer Gene Therapy 30, no. 1 (2023): 149–162.

[273] D. E. Johnson, B. Burtness, C. R. Leemans, V. W. Y. Lui, J. E. Bauman, and J. R. Grandis, “Head and Neck Squamous Cell Carcinoma,” Nature Reviews Disease Primers 6, no. 1 (2020): 92.

[274] M. D. Mody, J. W. Rocco, S. S. Yom, R. I. Haddad, and N. F. Saba, “Head and Neck Cancer,” Lancet 398, no. 10318 (2021): 2289–2299.

[275] L. Boucai, M. Zafereo, and M. E. Cabanillas, “Thyroid Cancer: A Review,” Jama 331, no. 5 (2024): 425–435.

[276] Y. P. Chen, A. T. C. Chan, Q. T. Le, P. Blanchard, Y. Sun, and J. Ma, “Nasopharyngeal Carcinoma,” Lancet 394, no. 10192 (2019): 64–80.

[277] C. E. Steuer, M. El-Deiry, J. R. Parks, K. A. Higgins, and N. F. Saba, “An Update on Larynx Cancer,” CA: A Cancer Journal for Clinicians 67, no. 1 (2017): 31–50.

[278] A. C. Chi, T. A. Day, and B. W. Neville, “Oral Cavity and Oropharyngeal Squamous Cell Carcinoma–an Update,” CA: A Cancer Journal for Clinicians 65, no. 5 (2015): 401–421.

[279] B. W. Neville and T. A. Day, “Oral Cancer and Precancerous Lesions,” CA: A Cancer Journal for Clinicians 52, no. 4 (2002): 195–215.

[280] J. L. Llorente, F. Lopez, C. Suarez, and M. A. Hermsen, “Sinonasal Carcinoma: Clinical, Pathological, Genetic and Therapeutic Advances,” Nature Reviews Clinical Oncology 11, no. 8 (2014): 460–472.

[281] H. Omori, M. Nishio, M. Masuda, et al., “YAP1 is a Potent Driver of the Onset and Progression of Oral Squamous Cell Carcinoma,” Science Advances 6, no. 12 (2020): eaay3324.

[282] S. V. Saladi, K. Ross, M. Karaayvaz, et al., “ACTL6A Is Co-Amplified With p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis,” Cancer Cell 31, no. 1 (2017): 35–49.

[283] K. C. W Wong, E. P. Hui, K. W. Lo, et al., “Nasopharyngeal Carcinoma: An Evolving Paradigm,” Nature Reviews Clinical Oncology 18, no. 11 (2021): 679–695.

[284] A. W. Lee, B. B. Ma, W. T. Ng, and A. T. Chan, “Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective,” Journal of Clinical Oncology 33, no. 29 (2015): 3356–3364.

[285] K. W. Lo, K. F. To, and D. P. Huang, “Focus on Nasopharyngeal Carcinoma,” Cancer Cell 5, no. 5 (2004): 423–428.

[286] C. Y. Lee, T. H. Wang, and Y. S. Kao, “Chemotherapy, Radiation Therapy, and Nasopharyngeal Carcinoma,” JAMA Oncology 10, no. 9 (2024): 1292–1293.

[287] Y. P. Liu, Y. H. Wen, J. Tang, et al., “Endoscopic Surgery Compared With Intensity-modulated Radiotherapy in Resectable Locally Recurrent Nasopharyngeal Carcinoma: A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial,” The Lancet Oncology 22, no. 3 (2021): 381–390.

[288] P. Wu, X. Hou, M. Peng, et al., “Circular RNA circRILPL1 Promotes Nasopharyngeal Carcinoma Malignant Progression by Activating the Hippo-YAP Signaling Pathway,” Cell Death and Differentiation 30, no. 7 (2023): 1679–1694.

[289] S. C. Liu, T. Hsu, Y. S. Chang, et al., “Cytoplasmic LIF Reprograms Invasive Mode to Enhance NPC Dissemination Through Modulating YAP1-FAK/PXN Signaling,” Nature Communications 9, no. 1 (2018): 5105.

[290] S. Beheshtirouy and A. Shayanfar, “A Review of Thyroid Cancer,” Jama 331, no. 21 (2024): 1862–1863.

[291] E. K. Alexander and E. S. Cibas, “Diagnosis of Thyroid Nodules,” The Lancet Diabetes & Endocrinology 10, no. 7 (2022): 533–539.

[292] C. M. Kitahara and J. A. Sosa, “The Changing Incidence of Thyroid Cancer,” Nature Reviews Endocrinology 12, no. 11 (2016): 646–653.

[293] Y. E. Nikiforov and M. N. Nikiforova, “Molecular Genetics and Diagnosis of Thyroid Cancer,” Nature Reviews Endocrinology 7, no. 10 (2011): 569–580.

[294] J. Tang, Q. Yang, C. Mao, et al., “The Deubiquitinating Enzyme UCHL3 Promotes Anaplastic Thyroid Cancer Progression and Metastasis Through Hippo Signaling Pathway,” Cell Death and Differentiation 30, no. 5 (2023): 1247–1259.

[295] M. E Garcia-Rendueles, J. C Ricarte-Filho, B. R. Untch, et al., “NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition,” Cancer Discovery 5, no. 11 (2015): 1178–1193.

[296] K. J. Wang, C. Wang, L. H. Dai, et al., “Targeting an Autocrine Regulatory Loop in Cancer Stem-Like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer,” Clinical Cancer Research 25, no. 3 (2019): 1070–1086.

[297] B. C. Widemann and A. Italiano, “Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives,” Journal of Clinical Oncology 36, no. 2 (2018): 160–167.

[298] W. Mo, J. Chen, A. Patel, et al., “CXCR4/CXCL12 mediate Autocrine Cell-cycle Progression in NF1-associated Malignant Peripheral Nerve Sheath Tumors,” Cell 152, no. 5 (2013): 1077–1090.

[299] F. J. Rodriguez, A. L. Folpe, C. Giannini, and A. Perry, “Pathology of Peripheral Nerve Sheath Tumors: Diagnostic Overview and Update on Selected Diagnostic Problems,” Acta Neuropathologica 123, no. 3 (2012): 295–319.

[300] L. M. N Wu, Y. Deng, J. Wang, et al., “Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis,” Cancer Cell 33, no. 2 (2018): 292–308. e297.

[301] M. L. Feltri and Y. Poitelon, “HIPPO Stampede in Nerve Sheath Tumors,” Cancer Cell 33, no. 2 (2018): 160–161.

[302] L. Laraba, L. Hillson, J. G. de Guibert, et al., “Inhibition of YAP/TAZ-driven TEAD Activity Prevents Growth of NF2-null Schwannoma and Meningioma,” Brain 146, no. 4 (2023): 1697–1713.

[303] G. V. Long, S. M. Swetter, A. M. Menzies, J. E. Gershenwald, and R. A. Scolyer, “Cutaneous Melanoma,” Lancet 402, no. 10400 (2023): 485–502.

[304] M. S. Carlino, J. Larkin, and G. V. Long, “Immune Checkpoint Inhibitors in Melanoma,” Lancet 398, no. 10304 (2021): 1002–1014.

[305] R. D. Carvajal, J. J. Sacco, M. J. Jager, et al., “Advances in the Clinical Management of Uveal Melanoma,” Nature Reviews Clinical Oncology 20, no. 2 (2023): 99–115.

[306] B. D. Curti and M. B. Faries, “Recent Advances in the Treatment of Melanoma,” New England Journal of Medicine 384, no. 23 (2021): 2229–2240.

[307] I. A. M Barbosa, R. Gopalakrishnan, S. Mercan, et al., “Cancer Lineage-specific Regulation of YAP Responsive Elements Revealed Through Large-scale Functional Epigenomic Screens,” Nature Communications 14, no. 1 (2023): 3907.

[308] X. Feng, M. S. Degese, R. Iglesias-Bartolome, et al., “Hippo-independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene Through a Trio-regulated Rho GTPase Signaling Circuitry,” Cancer Cell 25, no. 6 (2014): 831–845.

[309] X. Feng, N. Arang, D. C. Rigiracciolo, et al., “A Platform of Synthetic Lethal Gene Interaction Networks Reveals That the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway Through FAK,” Cancer Cell 35, no. 3 (2019): 457–472. e455.

[310] F. X. Yu, J. Luo, J. S. Mo, et al., “Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP,” Cancer Cell 25, no. 6 (2014): 822–830.

[311] A. Truong, J. H. Yoo, M. T. Scherzer, et al., “Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition,” Clinical Cancer Research 26, no. 23 (2020): 6374–6386.

[312] Y. Xiao, L. Zhou, T. Andl, and Y. Zhang, “YAP1 controls the N-cadherin-mediated Tumor-stroma Interaction in Melanoma Progression,” Oncogene 43, no. 12 (2024): 884–898.

[313] S. M. Swain, M. Shastry, and E. Hamilton, “Targeting HER2-positive Breast Cancer: Advances and Future Directions,” Nature Reviews Drug Discovery 22, no. 2 (2023): 101–126.

[314] E. Nolan, G. J. Lindeman, and J. E. Visvader, “Deciphering Breast Cancer: From Biology to the Clinic,” Cell 186, no. 8 (2023): 1708–1728.

[315] N. Harbeck, “Breast Cancer Is a Systemic Disease Optimally Treated by a Multidisciplinary Team,” Nature Reviews Disease Primers 6, no. 1 (2020): 30.

[316] N. Harbeck, F. Penault-Llorca, J. Cortes, et al., “Breast Cancer,” Nature Reviews Disease Primers 5, no. 1 (2019): 66.

[317] K. L. Britt, J. Cuzick, and K. A. Phillips, “Key Steps for Effective Breast Cancer Prevention,” Nature Reviews Cancer 20, no. 8 (2020): 417–436.

[318] M. Will, J. Liang, C. Metcalfe, and S. Chandarlapaty, “Therapeutic Resistance to Anti-oestrogen Therapy in Breast Cancer,” Nature Reviews Cancer 23, no. 10 (2023): 673–685.

[319] M. A. Harris, P. Savas, B. Virassamy, et al., “Towards Targeting the Breast Cancer Immune Microenvironment,” Nature Reviews Cancer 24, no. 8 (2024): 554–577.

[320] R. H. Li, T. Tian, Q. W. Ge, et al., “A Phosphatidic Acid-binding lncRNA SNHG9 Facilitates LATS1 Liquid-liquid Phase Separation to Promote Oncogenic YAP Signaling,” Cell Research 31, no. 10 (2021): 1088–1105.

[321] C. Li, S. Wang, Z. Xing, et al., “A ROR1-HER3-lncRNA Signalling Axis Modulates the Hippo-YAP Pathway to Regulate Bone Metastasis,” Nature Cell Biology 19, no. 2 (2017): 106–119.

[322] B. Ma, Y. Chen, L. Chen, et al., “Hypoxia Regulates Hippo Signalling Through the SIAH2 Ubiquitin E3 Ligase,” Nature Cell Biology 17, no. 1 (2015): 95–103.

[323] S. Ma, Z. Wu, F. Yang, et al., “Hippo Signalling Maintains ER Expression and ER(+) Breast Cancer Growth,” Nature 591, no. 7848 (2021): E1–E10.

[324] C. Zhu, L. Li, Z. Zhang, et al., “A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer,” Molecular Cell 75, no. 4 (2019): 791–806. e798.

[325] H. Han, R. Qi, J. J. Zhou, et al., “Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction,” Molecular Cell 72, no. 2 (2018): 328–340. e328.

[326] Y. Gao, Y. Yang, F. Yuan, et al., “TNFalpha-YAP/p65-HK2 Axis Mediates Breast Cancer Cell Migration,” Oncogenesis 6, no. 9 (2017): e383.

[327] S. Wang, E. Englund, P. Kjellman, et al., “CCM3 is a Gatekeeper in Focal Adhesions Regulating Mechanotransduction and YAP/TAZ Signalling,” Nature Cell Biology 23, no. 7 (2021): 758–770.

[328] G. Sorrentino, N. Ruggeri, V. Specchia, et al., “Metabolic Control of YAP and TAZ by the Mevalonate Pathway,” Nature Cell Biology 16, no. 4 (2014): 357–366.

[329] J. Zhang, J. Y. Ji, M. Yu, et al., “YAP-dependent Induction of Amphiregulin Identifies a Non-Cell-Autonomous Component of the Hippo Pathway,” Nature Cell Biology 11, no. 12 (2009): 1444–1450.

[330] J. Kim, H. L. Piao, B. J. Kim, et al., “Long Noncoding RNA MALAT1 Suppresses Breast Cancer Metastasis,” Nature Genetics 50, no. 12 (2018): 1705–1715.

[331] B. von Eyss, L. A. Jaenicke, R. M. Kortlever, et al., “A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer,” Cancer Cell 28, no. 6 (2015): 743–757.

[332] E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. van Grieken, and F. Lordick, “Gastric Cancer,” Lancet 396, no. 10251 (2020): 635–648.

[333] E. Van Cutsem, X. Sagaert, B. Topal, K. Haustermans, and H. Prenen, “Gastric Cancer,” Lancet 388, no. 10060 (2016): 2654–2664.

[334] S. S. Joshi and B. D. Badgwell, “Current Treatment and Recent Progress in Gastric Cancer,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 264–279.

[335] M. Alsina, V. Arrazubi, M. Diez, and J. Tabernero, “Current Developments in Gastric Cancer: From Molecular Profiling to Treatment Strategy,” Nature Reviews Gastroenterology & Hepatology 20, no. 3 (2023): 155–170.

[336] M. Amieva, “Pathobiology of Helicobacter pylori-Induced Gastric Cancer,” Gastroenterology 150, no. 1 (2016): 64–78.

[337] M. H. McLean and E. M. El-Omar, “Genetics of Gastric Cancer,” Nature Reviews Gastroenterology & Hepatology 11, no. 11 (2014): 664–674.

[338] T. Ushijima and M. Sasako, “Focus on Gastric Cancer,” Cancer Cell 5, no. 2 (2004): 121–125.

[339] W. Kang, J. H. Tong, A. W. Chan, et al., “Yes-associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates With Poor Prognosis,” Clinical Cancer Research 17, no. 8 (2011): 2130–2139.

[340] Y. Tang, G. Fang, F. Guo, et al., “Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer,” Cancer Cell 38, no. 1 (2020): 115–128. e119.

[341] L. An, P. Nie, M. Chen, et al., “MST4 kinase Suppresses Gastric Tumorigenesis by Limiting YAP Activation via a Non-canonical Pathway,” Journal of Experimental Medicine 217, no. 6 (2020): e20191817.

[342] N. Li, X. Xu, Y. Zhan, et al., “YAP and Beta-catenin Cooperate to Drive H. pylori-induced Gastric Tumorigenesis,” Gut Microbes 15, no. 1 (2023): 2192501.

[343] F. Zhang, V. Sahu, K. Peng, et al., “Recurrent RhoGAP Gene Fusion CLDN18-ARHGAP26 Promotes RHOA Activation and Focal Adhesion Kinase and YAP-TEAD Signalling in Diffuse Gastric Cancer,” Gut 73, no. 8 (2024): 1280–1291.

[344] S. Jiao, J. Guan, M. Chen, et al., “Targeting IRF3 as a YAP Agonist Therapy Against Gastric Cancer,” Journal of Experimental Medicine 215, no. 2 (2018): 699–718.

[345] M. Jang, J. An, S. W. Oh, et al., “Matrix Stiffness Epigenetically Regulates the Oncogenic Activation of the Yes-associated Protein in Gastric Cancer,” Nature Biomedical Engineering 5, no. 1 (2021): 114–123.

[346] J. Ju, H. Zhang, M. Lin, et al., “The Alanyl-tRNA Synthetase AARS1 Moonlights as a Lactyltransferase to Promote YAP Signaling in Gastric Cancer,” Journal of Clinical Investigation 134, no. 10 (2024): e174587.

[347] P. Nie, W. Zhang, Y. Meng, et al., “A YAP/TAZ-CD54 Axis Is Required for CXCR2-CD44-tumor-specific Neutrophils to Suppress Gastric Cancer,” Protein Cell 14, no. 7 (2023): 513–531.

[348] W. Kang, J. H. Tong, R. W. Lung, et al., “Targeting of YAP1 by microRNA-15a and microRNA-16-1 Exerts Tumor Suppressor Function in Gastric Adenocarcinoma,” Molecular Cancer 14 (2015): 52.

[349] S. Jiao, H. Wang, Z. Shi, et al., “A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy Against Gastric Cancer,” Cancer Cell 25, no. 2 (2014): 166–180.

[350] M. A. van den Bosch and L. Defreyne, “Hepatocellular Carcinoma,” Lancet 380, no. 9840 (2012): 469–470. author reply 470-461.

[351] X. Li, P. Ramadori, D. Pfister, M. Seehawer, L. Zender, and M. Heikenwalder, “The Immunological and Metabolic Landscape in Primary and Metastatic Liver Cancer,” Nature Reviews Cancer 21, no. 9 (2021): 541–557.

[352] M. Ringelhan, D. Pfister, T. O’Connor, E. Pikarsky, and M. Heikenwalder, “The Immunology of Hepatocellular Carcinoma,” Nature Immunology 19, no. 3 (2018): 222–232.

[353] A. G. Singal, F. Kanwal, and J. M. Llovet, “Global Trends in Hepatocellular Carcinoma Epidemiology: Implications for Screening, Prevention and Therapy,” Nature Reviews Clinical Oncology 20, no. 12 (2023): 864–884.

[354] J. M. Llovet, R. Montal, D. Sia, and R. S. Finn, “Molecular Therapies and Precision Medicine for Hepatocellular Carcinoma,” Nature Reviews Clinical Oncology 15, no. 10 (2018): 599–616.

[355] S. Abitbol, R. Dahmani, C. Coulouarn, et al., “AXIN Deficiency in human and Mouse Hepatocytes Induces Hepatocellular Carcinoma in the Absence of Beta-catenin Activation,” Journal of Hepatology 68, no. 6 (2018): 1203–1213.

[356] L. Zender, M. S. Spector, W. Xue, et al., “Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach,” Cell 125, no. 7 (2006): 1253–1267.

[357] A. Perra, M. A. Kowalik, E. Ghiso, et al., “YAP Activation Is an Early Event and a Potential Therapeutic Target in Liver Cancer Development,” Journal of Hepatology 61, no. 5 (2014): 1088–1096.

[358] S. M. E Weiler, F. Pinna, T. Wolf, et al., “Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer,” Gastroenterology 152, no. 8 (2017): 2037–2051. e2022.

[359] S. H. Patel, F. D. Camargo, and D. Yimlamai, “Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis,” Gastroenterology 152, no. 3 (2017): 533–545.

[360] K. Cho, S. W. Ro, H. W. Lee, et al., “YAP/TAZ Suppress Drug Penetration into Hepatocellular Carcinoma through Stromal Activation,” Hepatology 74, no. 5 (2021): 2605–2621.

[361] Y. Tian, B. Yang, W. Qiu, et al., “ER-residential Nogo-B Accelerates NAFLD-associated HCC Mediated by Metabolic Reprogramming of oxLDL Lipophagy,” Nature Communications 10, no. 1 (2019): 3391.

[362] X. Sun, Y. Ding, M. Zhan, et al., “Usp7 regulates Hippo Pathway Through Deubiquitinating the Transcriptional Coactivator Yorkie,” Nature Communications 10, no. 1 (2019): 411.

[363] M. A. Kowalik, C. Saliba, M. Pibiri, et al., “Yes-associated Protein Regulation of Adaptive Liver Enlargement and Hepatocellular Carcinoma Development in Mice,” Hepatology 53, no. 6 (2011): 2086–2096.

[364] H. Wang, S. Zhang, Y. Zhang, et al., “TAZ Is Indispensable for c-MYC-induced Hepatocarcinogenesis,” Journal of Hepatology 76, no. 1 (2022): 123–134.

[365] R. Urtasun, M. U. Latasa, M. I. Demartis, et al., “Connective Tissue Growth Factor Autocriny in human Hepatocellular Carcinoma: Oncogenic Role and Regulation by Epidermal Growth Factor Receptor/Yes-associated Protein-mediated Activation,” Hepatology 54, no. 6 (2011): 2149–2158.

[366] W. Ni, Y. Zhang, Z. Zhan, et al., “A Novel lncRNA Uc.134 Represses Hepatocellular Carcinoma Progression by Inhibiting CUL4A-mediated Ubiquitination of LATS1,” Journal of Hematology & Oncology 10, no. 1 (2017): 91.

[367] D. Su, Y. Li, W. Zhang, et al., “SPTAN1/NUMB Axis Senses Cell Density to Restrain Cell Growth and Oncogenesis Through Hippo Signaling,” Journal of Clinical Investigation 133, no. 20 (2023): e168888.

[368] A. Hermann, D. O. Wennmann, S. Gromnitza, et al., “WW and C2 Domain-containing Proteins Regulate Hepatic Cell Differentiation and Tumorigenesis Through the Hippo Signaling Pathway,” Hepatology 67, no. 4 (2018): 1546–1559.

[369] J. Hyun, M. Al Abo, R. K. Dutta, et al., “Dysregulation of the ESRP2-NF2-YAP/TAZ Axis Promotes Hepatobiliary Carcinogenesis in Non-alcoholic Fatty Liver Disease,” Journal of Hepatology 75, no. 3 (2021): 623–633.

[370] X. M. Yang, X. Y. Cao, P. He, et al., “Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis,” Gastroenterology 155, no. 4 (2018): 1233–1249. e1222.

[371] Y. X. Xiong, X. C. Zhang, J. H. Zhu, et al., “Collagen I-DDR1 Signaling Promotes Hepatocellular Carcinoma Cell Stemness via Hippo Signaling Repression,” Cell Death and Differentiation 30, no. 7 (2023): 1648–1665.

[372] W. Kim, S. K. Khan, Y. Liu, et al., “Hepatic Hippo Signaling Inhibits Protumoural Microenvironment to Suppress Hepatocellular Carcinoma,” Gut 67, no. 9 (2018): 1692–1703.

[373] S. Zhang, Q. Chen, Q. Liu, et al., “Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis Through Skp2,” Cancer Cell 31, no. 5 (2017): 669–684. e667.

[374] D. Zhou, C. Conrad, F. Xia, et al., “Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development Through Inactivation of the Yap1 Oncogene,” Cancer Cell 16, no. 5 (2009): 425–438.

[375] T. Zhang, J. Zhang, X. You, et al., “Hepatitis B Virus X Protein Modulates Oncogene Yes-associated Protein by CREB to Promote Growth of Hepatoma Cells,” Hepatology 56, no. 6 (2012): 2051–2059.

[376] T. J. Hagenbeek, J. D. Webster, N. M. Kljavin, et al., “The Hippo Pathway Effector TAZ Induces TEAD-dependent Liver Inflammation and Tumors,” Science Signaling 11, no. 547 (2018): eaaj1757.

[377] B. Liang, Y. Zhou, M. Qian, et al., “TBX3 functions as a Tumor Suppressor Downstream of Activated CTNNB1 Mutants During Hepatocarcinogenesis,” Journal of Hepatology 75, no. 1 (2021): 120–131.

[378] K. Tu, W. Yang, C. Li, et al., “Fbxw7 is an Independent Prognostic Marker and Induces Apoptosis and Growth Arrest by Regulating YAP Abundance in Hepatocellular Carcinoma,” Molecular Cancer 13 (2014): 110.

[379] H. Wang, X. Song, H. Liao, et al., “Overexpression of Mothers against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans,” Hepatology 74, no. 1 (2021): 248–263.

[380] R. Chen, S. Zhu, X. G. Fan, et al., “High Mobility Group Protein B1 Controls Liver Cancer Initiation Through Yes-associated Protein - dependent Aerobic Glycolysis,” Hepatology 67, no. 5 (2018): 1823–1841.

[381] W. X. Ding and P. Sancho-Bru, “SOX9 acts Downstream of YAP to Decide Liver Cell Fate and Tumor Types,” Journal of Hepatology 76, no. 3 (2022): 503–505.

[382] K. Li, J. Zhang, H. Lyu, et al., “CSN6-SPOP-HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation,” Advanced Science (Weinh) 11, no. 14 (2024): e2306827.

[383] Y. Saito, D. Yin, N. Kubota, et al., “A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23,” Gastroenterology 164, no. 7 (2023): 1279–1292.

[384] J. Tao, D. F. Calvisi, S. Ranganathan, et al., “Activation of Beta-catenin and Yap1 in human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice,” Gastroenterology 147, no. 3 (2014): 690–701.

[385] M. Lin, X. Zheng, J. Yan, et al., “The RNF214-TEAD-YAP Signaling Axis Promotes Hepatocellular Carcinoma Progression via TEAD Ubiquitylation,” Nature Communications 15, no. 1 (2024): 4995.

[386] B. Liang, H. Wang, Y. Qiao, et al., “Differential Requirement of Hippo Cascade During CTNNB1 or AXIN1 Mutation-driven Hepatocarcinogenesis,” Hepatology 77, no. 6 (2023): 1929–1942.

[387] T. Yuan, T. Zhou, M. Qian, et al., “SDHA/B Reduction Promotes Hepatocellular Carcinoma by Facilitating the deNEDDylation of cullin1 and Stabilizing YAP/TAZ,” Hepatology 78, no. 1 (2023): 103–119.

[388] W. C. Yuan, B. Pepe-Mooney, G. G. Galli, et al., “NUAK2 is a Critical YAP Target in Liver Cancer,” Nature Communications 9, no. 1 (2018): 4834.

[389] W. Kim, S. K. Khan, J. Gvozdenovic-Jeremic, et al., “Hippo Signaling Interactions With Wnt/Beta-catenin and Notch Signaling Repress Liver Tumorigenesis,” Journal of Clinical Investigation 127, no. 1 (2017): 137–152.

[390] W. Y. Cai, L. Y. Lin, H. Hao, et al., “Yes-associated Protein/TEA Domain family Member and Hepatocyte Nuclear Factor 4-alpha (HNF4alpha) Repress Reciprocally to Regulate Hepatocarcinogenesis in Rats and Mice,” Hepatology 65, no. 4 (2017): 1206–1221.

[391] J. Wang, L. Ma, W. Weng, et al., “Mutual Interaction Between YAP and CREB Promotes Tumorigenesis in Liver Cancer,” Hepatology 58, no. 3 (2013): 1011–1020.

[392] J. Wang, J. S. Park, Y. Wei, et al., “TRIB2 acts Downstream of Wnt/TCF in Liver Cancer Cells to Regulate YAP and C/EBPalpha Function,” Molecular Cell 51, no. 2 (2013): 211–225.

[393] X. Luo, R. Zhang, S. Schefczyk, et al., “Nuclear Translocation of YAP Drives BMI-associated Hepatocarcinogenesis in hepatitis B Virus Infection,” Liver International 43, no. 9 (2023): 2002–2016.

[394] D. Wu, G. Liu, Y. Liu, et al., “Zinc Finger Protein 191 Inhibits Hepatocellular Carcinoma Metastasis Through Discs Large 1-mediated Yes-associated Protein Inactivation,” Hepatology 64, no. 4 (2016): 1148–1162.

[395] A. G. Cox, K. L. Hwang, K. K. Brown, et al., “Yap Reprograms Glutamine Metabolism to Increase Nucleotide Biosynthesis and Enable Liver Growth,” Nature Cell Biology 18, no. 8 (2016): 886–896.

[396] Y. Y. Park, B. H. Sohn, R. L. Johnson, et al., “Yes-associated Protein 1 and Transcriptional Coactivator With PDZ-binding Motif Activate the Mammalian Target of Rapamycin Complex 1 Pathway by Regulating Amino Acid Transporters in Hepatocellular Carcinoma,” Hepatology 63, no. 1 (2016): 159–172.

[397] K. Martin, J. Pritchett, J. Llewellyn, et al., “PAK Proteins and YAP-1 Signalling Downstream of Integrin Beta-1 in Myofibroblasts Promote Liver Fibrosis,” Nature Communications 7 (2016): 12502.

[398] S. H. Jeong, H. B. Kim, M. C. Kim, et al., “Hippo-mediated Suppression of IRS2/AKT Signaling Prevents Hepatic Steatosis and Liver Cancer,” Journal of Clinical Investigation 128, no. 3 (2018): 1010–1025.

[399] D. F. Tschaharganeh, X. Chen, P. Latzko, et al., “Yes-associated Protein Up-regulates Jagged-1 and Activates the Notch Pathway in human Hepatocellular Carcinoma,” Gastroenterology 144, no. 7 (2013): 1530–1542. e1512.

[400] N. Razumilava and G. J. Gores, “Cholangiocarcinoma,” Lancet 383, no. 9935 (2014): 2168–2179.

[401] P. J. Brindley, M. Bachini, S. I. Ilyas, et al., “Cholangiocarcinoma,” Nature Reviews Disease Primers 7, no. 1 (2021): 65.

[402] S. I. Ilyas, S. Affo, L. Goyal, et al., “Cholangiocarcinoma—novel Biological Insights and Therapeutic Strategies,” Nature Reviews Clinical Oncology 20, no. 7 (2023): 470–486.

[403] T. F. Greten, R. Schwabe, N. Bardeesy, et al., “Immunology and Immunotherapy of Cholangiocarcinoma,” Nature Reviews Gastroenterology & Hepatology 20, no. 6 (2023): 349–365.

[404] R. K. Kelley, J. Bridgewater, G. J. Gores, and A. X. Zhu, “Systemic Therapies for Intrahepatic Cholangiocarcinoma,” Journal of Hepatology 72, no. 2 (2020): 353–363.

[405] S. Xu, Z. Yuan, C. Jiang, W. Chen, Q. Li, and T. Chen, “DNMT3A Cooperates With YAP/TAZ to Drive Gallbladder Cancer Metastasis,” Advanced Science (Weinh) 11, no. 16 (2024): e2308531.

[406] J. Li, N. Razumilava, G. J. Gores, et al., “Biliary Repair and Carcinogenesis Are Mediated by IL-33-dependent Cholangiocyte Proliferation,” Journal of Clinical Investigation 124, no. 7 (2014): 3241–3251.

[407] Y. Zhang, H. Xu, G. Cui, et al., “beta-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma,” Gastroenterology 163, no. 2 (2022): 481–494.

[408] J. P. Neoptolemos, C. Springfeld, and T. Hackert, “A Review of Pancreatic Cancer,” Jama 326, no. 23 (2021): 2436.

[409] W. Park, A. Chawla, and E. M. O’Reilly, “Pancreatic Cancer: A Review,” Jama 326, no. 9 (2021): 851–862.

[410] C. J. Halbrook, C. A. Lyssiotis, M. Pasca di Magliano, and A. Maitra, “Pancreatic Cancer: Advances and Challenges,” Cell 186, no. 8 (2023): 1729–1754.

[411] J. Kleeff, M. Korc, M. Apte, et al., “Pancreatic Cancer,” Nature Reviews Disease Primers 2 (2016): 16022.

[412] A. P. Klein, “Pancreatic Cancer Epidemiology: Understanding the Role of Lifestyle and Inherited Risk Factors,” Nature Reviews Gastroenterology & Hepatology 18, no. 7 (2021): 493–502.

[413] Z. I. Hu and E. M. O’Reilly, “Therapeutic Developments in Pancreatic Cancer,” Nature Reviews Gastroenterology & Hepatology 21, no. 1 (2024): 7–24.

[414] J. P. Neoptolemos, J. Kleeff, P. Michl, E. Costello, W. Greenhalf, and D. H. Palmer, “Therapeutic Developments in Pancreatic Cancer: Current and Future Perspectives,” Nature Reviews Gastroenterology & Hepatology 15, no. 6 (2018): 333–348.

[415] M. Liu, Y. Zhang, J. Yang, et al., “Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer,” Gastroenterology 160, no. 5 (2021): 1771–1783. e1771.

[416] A. Kapoor, W. Yao, H. Ying, et al., “Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer,” Cell 158, no. 1 (2014): 185–197.

[417] I. Cebola, S. A Rodriguez-Segui, C. H. Cho, et al., “TEAD and YAP Regulate the Enhancer Network of human Embryonic Pancreatic Progenitors,” Nature Cell Biology 17, no. 5 (2015): 615–626.

[418] F. Li, V. Negi, P. Yang, et al., “TEAD1 regulates Cell Proliferation Through a Pocket-independent Transcription Repression Mechanism,” Nucleic Acids Research 50, no. 22 (2022): 12723–12738.

[419] R. Gruber, R. Panayiotou, E. Nye, B. Spencer-Dene, G. Stamp, and A. Behrens, “YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling,” Gastroenterology 151, no. 3 (2016): 526–539.

[420] S. Shen, X. Guo, H. Yan, et al., “A miR-130a-YAP Positive Feedback Loop Promotes Organ Size and Tumorigenesis,” Cell Research 25, no. 9 (2015): 997–1012.

[421] J. Liu, W. Bai, T. Zhou, et al., “SDCBP Promotes Pancreatic Cancer Progression by Preventing YAP1 From Beta-TrCP-mediated Proteasomal Degradation,” Gut 72, no. 9 (2023): 1722–1737.

[422] C. Zhao, J. Gong, Y. Bai, et al., “A Self-amplifying USP14-TAZ Loop Drives the Progression and Liver Metastasis of Pancreatic Ductal Adenocarcinoma,” Cell Death and Differentiation 30, no. 1 (2023): 1–15.

[423] X. Luo, N. A. Campbell, L. He, et al., “Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis,” Hepatology 74, no. 3 (2021): 1411–1428.

[424] N. Li, G. Yang, L. Luo, et al., “lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting With YAP,” Clinical Cancer Research 26, no. 7 (2020): 1736–1748.

[425] E. Cortes, M. Sarper, B. Robinson, et al., “GPER Is a Mechanoregulator of Pancreatic Stellate Cells and the Tumor Microenvironment,” Embo Reports 20, no. 1 (2019): e46556.

[426] S. S. Mello, L. J. Valente, N. Raj, et al., “A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer,” Cancer Cell 32, no. 4 (2017): 460–473. e466.

[427] Y. Aylon and M. Oren, “Tumor Suppression by p53: Bring in the Hippo!,” Cancer Cell 32, no. 4 (2017): 397–399.

[428] E. Dekker, P. J. Tanis, J. L. A. Vleugels, P. M. Kasi, and M. B. Wallace, “Colorectal Cancer,” Lancet 394, no. 10207 (2019): 1467–1480.

[429] L. H. Biller and D. Schrag, “Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review,” Jama 325, no. 7 (2021): 669–685.

[430] M. C. W Spaander, A. G. Zauber, S. Syngal, et al., “Young-onset Colorectal Cancer,” Nature Reviews Disease Primers 9, no. 1 (2023): 21.

[431] E. J. Kuipers, W. M. Grady, D. Lieberman, et al., “Colorectal Cancer,” Nature Reviews Disease Primers 1 (2015): 15065.

[432] N. Keum and E. Giovannucci, “Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies,” Nature Reviews Gastroenterology & Hepatology 16, no. 12 (2019): 713–732.

[433] C. Eng, T. Yoshino, E. Ruiz-Garcia, et al., “Colorectal Cancer,” Lancet 404, no. 10449 (2024): 294–310.

[434] J. Weitz, M. Koch, J. Debus, T. Hohler, P. R. Galle, and M. W. Buchler, “Colorectal Cancer,” Lancet 365, no. 9454 (2005): 153–165.

[435] K. W. Lee, S. S. Lee, S. B. Kim, et al., “Significant Association of Oncogene YAP1 With Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients,” Clinical Cancer Research 21, no. 2 (2015): 357–364.

[436] E. R. Barry, T. Morikawa, B. L. Butler, et al., “Restriction of Intestinal Stem Cell Expansion and the Regenerative Response by YAP,” Nature 493, no. 7430 (2013): 106–110.

[437] G. Della Chiara, F. Gervasoni, M. Fakiola, et al., “Epigenomic Landscape of human Colorectal Cancer Unveils an Aberrant Core of Pan-cancer Enhancers Orchestrated by YAP/TAZ,” Nature Communications 12, no. 1 (2021): 2340.

[438] L. Fang, H. Teng, Y. Wang, et al., “SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis,” Cancer Cell 34, no. 1 (2018): 103–118. e109.

[439] Q. Wang, X. Gao, T. Yu, et al., “REGgamma Controls Hippo Signaling and Reciprocal NF-kappaB-YAP Regulation to Promote Colon Cancer,” Clinical Cancer Research 24, no. 8 (2018): 2015–2025.

[440] J. Xu, Y. Tang, X. Sheng, et al., “Secreted Stromal Protein ISLR Promotes Intestinal Regeneration by Suppressing Epithelial Hippo Signaling,” Embo Journal 39, no. 7 (2020): e103255.

[441] Y. Pan, J. H. M. Tong, R. W. M. Lung, et al., “RASAL2 promotes Tumor Progression Through LATS2/YAP1 Axis of Hippo Signaling Pathway in Colorectal Cancer,” Molecular Cancer 17, no. 1 (2018): 102.

[442] K. Zeng, J. Peng, Y. Xing, et al., “A Positive Feedback Circuit Driven by M(6)A-modified Circular RNA Facilitates Colorectal Cancer Liver Metastasis,” Molecular Cancer 22, no. 1 (2023): 202.

[443] H. B. Kim, M. Kim, Y. S. Park, et al., “Prostaglandin E(2) Activates YAP and a Positive-Signaling Loop to Promote Colon Regeneration after Colitis but Also Carcinogenesis in Mice,” Gastroenterology 152, no. 3 (2017): 616–630.

[444] Y. Touil, W. Igoudjil, M. Corvaisier, et al., “Colon Cancer Cells Escape 5FU Chemotherapy-induced Cell Death by Entering Stemness and Quiescence Associated With the c-Yes/YAP Axis,” Clinical Cancer Research 20, no. 4 (2014): 837–846.

[445] N. Ferrari, R. Ranftl, I. Chicherova, et al., “Dickkopf-3 Links HSF1 and YAP/TAZ Signalling to Control Aggressive Behaviours in Cancer-associated Fibroblasts,” Nature Communications 10, no. 1 (2019): 130.

[446] Y. Gu, Y. Chen, L. Wei, et al., “ABHD5 inhibits YAP-induced c-Met Overexpression and Colon Cancer Cell Stemness via Suppressing YAP Methylation,” Nature Communications 12, no. 1 (2021): 6711.

[447] Y. Guo, Z. Zhu, Z. Huang, et al., “CK2-induced Cooperation of HHEX With the YAP-TEAD4 Complex Promotes Colorectal Tumorigenesis,” Nature Communications 13, no. 1 (2022): 4995.

[448] Q. Pan, S. Zhong, H. Wang, et al., “The ZMYND8-regulated Mevalonate Pathway Endows YAP-high Intestinal Cancer With Metabolic Vulnerability,” Molecular Cell 81, no. 13 (2021): 2736–2751. e2738.

[449] S. Jiao, C. Li, Q. Hao, et al., “VGLL4 targets a TCF4-TEAD4 Complex to Coregulate Wnt and Hippo Signalling in Colorectal Cancer,” Nature Communications 8 (2017): 14058.

[450] H. Y. Wang, Q. Y. Long, S. B. Tang, et al., “Histone Demethylase KDM3A Is Required for Enhancer Activation of Hippo Target Genes in Colorectal Cancer,” Nucleic Acids Research 47, no. 5 (2019): 2349–2364.

[451] H. Xu, S. Zhou, H. Xia, H. Yu, Q. Tang, and F. Bi, “MEK Nuclear Localization Promotes YAP Stability via Sequestering Beta-TrCP in KRAS Mutant Cancer Cells,” Cell Death and Differentiation 26, no. 11 (2019): 2400–2415.

[452] B. Pan, Y. Yang, J. Li, et al., “USP47-mediated Deubiquitination and Stabilization of YAP Contributes to the Progression of Colorectal Cancer,” Protein Cell 11, no. 2 (2020): 138–143.

[453] M. Sun, H. Song, S. Wang, et al., “Integrated Analysis Identifies microRNA-195 as a Suppressor of Hippo-YAP Pathway in Colorectal Cancer,” Journal of Hematology & Oncology 10, no. 1 (2017): 79.

[454] Z. Diamantopoulou, G. White, M. Z. H. Fadlullah, et al., “TIAM1 Antagonizes TAZ/YAP both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells,” Cancer Cell 31, no. 5 (2017): 621–634. e626.

[455] L. E. L Hendriks, J. Remon, C. Faivre-Finn, et al., “Non-small-cell Lung Cancer,” Nature Reviews Disease Primers 10, no. 1 (2024): 71.

[456] C. Gridelli, A. Rossi, D. P. Carbone, et al., “Non-small-cell Lung Cancer,” Nature Reviews Disease Primers 1 (2015): 15009.

[457] A. A. Thai, B. J. Solomon, L. V. Sequist, J. F. Gainor, and R. S. Heist, “Lung Cancer,” Lancet 398, no. 10299 (2021): 535–554.

[458] R. Barnett, “Lung Cancer,” Lancet 390, no. 10098 (2017): 928.

[459] S. C. M Lau, Y. Pan, V. Velcheti, and K. K. Wong, “Squamous Cell Lung Cancer: Current Landscape and Future Therapeutic Options,” Cancer Cell 40, no. 11 (2022): 1279–1293.

[460] F. R. Hirsch, G. V. Scagliotti, J. L. Mulshine, et al., “Lung Cancer: Current Therapies and New Targeted Treatments,” Lancet 389, no. 10066 (2017): 299–311.

[461] R. S. Herbst, D. Morgensztern, and C. Boshoff, “The Biology and Management of Non-small Cell Lung Cancer,” Nature 553, no. 7689 (2018): 446–454.

[462] A. Lahiri, A. Maji, P. D. Potdar, et al., “Lung Cancer Immunotherapy: Progress, Pitfalls, and Promises,” Molecular Cancer 22, no. 1 (2023): 40.

[463] S. M. Pearsall, S. Humphrey, M. Revill, et al., “The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report,” Journal of Thoracic Oncology 15, no. 12 (2020): 1836–1843.

[464] Y. T. Shue, A. P. Drainas, N. Y. Li, et al., “A Conserved YAP/Notch/REST Network Controls the Neuroendocrine Cell Fate in the Lungs,” Nature Communications 13, no. 1 (2022): 2690.

[465] B. Zhou, P. Flodby, J. Luo, et al., “Claudin-18-mediated YAP Activity Regulates Lung Stem and Progenitor Cell Homeostasis and Tumorigenesis,” Journal of Clinical Investigation 128, no. 3 (2018): 970–984.

[466] D. N. Kotton, “Claudin-18: Unexpected Regulator of Lung Alveolar Epithelial Cell Proliferation,” Journal of Clinical Investigation 128, no. 3 (2018): 903–905.

[467] X. Rong, Y. Liang, Q. Han, et al., “Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor,” Journal of Thoracic Oncology 14, no. 10 (2019): 1766–1783.

[468] J. Jin, L. Zhang, X. Li, et al., “Oxidative Stress-CBP Axis Modulates MOB1 Acetylation and Activates the Hippo Signaling Pathway,” Nucleic Acids Research 50, no. 7 (2022): 3817–3834.

[469] C. Xu, G. Jin, H. Wu, et al., “SIRPgamma-expressing Cancer Stem-Like Cells Promote Immune Escape of Lung Cancer via Hippo Signaling,” Journal of Clinical Investigation 132, no. 5 (2022): e141797.

[470] D. Jin, J. Guo, Y. Wu, et al., “m(6)A Demethylase ALKBH5 Inhibits Tumor Growth and Metastasis by Reducing YTHDFs-mediated YAP Expression and Inhibiting miR-107/LATS2-mediated YAP Activity in NSCLC,” Molecular Cancer 19, no. 1 (2020): 40.

[471] I. Chaib, N. Karachaliou, S. Pilotto, et al., “Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC,” JNCI: Journal of the National Cancer Institute 109, no. 9 (2017): djx014.

[472] K. J. Kurppa, Y. Liu, C. To, et al., “Treatment-Induced Tumor Dormancy Through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway,” Cancer Cell 37, no. 1 (2020): 104–122. e112.

[473] Y. Gao, W. Zhang, X. Han, et al., “YAP Inhibits Squamous Transdifferentiation of Lkb1-Deficient Lung Adenocarcinoma Through ZEB2-dependent DNp63 Repression,” Nature Communications 5 (2014): 4629.

[474] T. Tsuji, H. Ozasa, W. Aoki, et al., “YAP1 mediates Survival of ALK-rearranged Lung Cancer Cells Treated With alectinib via Pro-apoptotic Protein Regulation,” Nature Communications 11, no. 1 (2020): 74.

[475] U. Capitanio and F. Montorsi, “Renal Cancer,” Lancet 387, no. 10021 (2016): 894–906.

[476] J. J. Hsieh, M. P. Purdue, S. Signoretti, et al., “Renal Cell Carcinoma,” Nature Reviews Disease Primers 3 (2017): 17009.

[477] P. C. Barata and B. I. Rini, “Treatment of Renal Cell Carcinoma: Current Status and Future Directions,” CA: A Cancer Journal for Clinicians 67, no. 6 (2017): 507–524.

[478] S. Chevrier, J. H. Levine, V. R. T. Zanotelli, et al., “An Immune Atlas of Clear Cell Renal Cell Carcinoma,” Cell 169, no. 4 (2017): 736–749. e718.

[479] W. K. Rathmell, R. B. Rumble, P. J. Van Veldhuizen, et al., “Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline,” Journal of Clinical Oncology 40, no. 25 (2022): 2957–2995.

[480] L. Qu, Z. Wu, Y. Li, et al., “A Feed-forward Loop Between lncARSR and YAP Activity Promotes Expansion of Renal Tumour-initiating Cells,” Nature Communications 7 (2016): 12692.

[481] C. Wang, Y. Wang, T. Hong, et al., “Targeting a Positive Regulatory Loop in the Tumor-macrophage Interaction Impairs the Progression of Clear Cell Renal Cell Carcinoma,” Cell Death and Differentiation 28, no. 3 (2021): 932–951.

[482] T. He, Q. Zhang, P. Xu, et al., “Extracellular Vesicle-circEHD2 Promotes the Progression of Renal Cell Carcinoma by Activating Cancer-associated Fibroblasts,” Molecular Cancer 22, no. 1 (2023): 117.

[483] P. Carter, U. Schnell, C. Chaney, et al., “Deletion of Lats1/2 in Adult Kidney Epithelia Leads to Renal Cell Carcinoma,” Journal of Clinical Investigation 131, no. 11 (2021): e144108.

[484] A. T. Lenis, P. M. Lec, K. Chamie, and M. D. Mshs, “Bladder Cancer: A Review,” Jama 324, no. 19 (2020): 1980–1991.

[485] L. Dyrskjot, D. E. Hansel, J. A. Efstathiou, et al., “Bladder Cancer,” Nature Reviews Disease Primers 9, no. 1 (2023): 58.

[486] O. Sanli, J. Dobruch, M. A. Knowles, et al., “Bladder Cancer,” Nature Reviews Disease Primers 3 (2017): 17022.

[487] E. Comperat, M. B. Amin, R. Cathomas, et al., “Current Best Practice for Bladder Cancer: A Narrative Review of Diagnostics and Treatments,” Lancet 400, no. 10364 (2022): 1712–1721.

[488] M. A. Knowles and C. D. Hurst, “Molecular Biology of Bladder Cancer: New Insights Into Pathogenesis and Clinical Diversity,” Nature Reviews Cancer 15, no. 1 (2015): 25–41.

[489] C. P. Dinney, D. J. McConkey, R. E. Millikan, et al., “Focus on Bladder Cancer,” Cancer Cell 6, no. 2 (2004): 111–116.

[490] D. J. Parekh, B. H. Bochner, and G. Dalbagni, “Superficial and Muscle-invasive Bladder Cancer: Principles of Management for Outcomes Assessments,” Journal of Clinical Oncology 24, no. 35 (2006): 5519–5527.

[491] F. M. Torti and B. L. Lum, “The Biology and Treatment of Superficial Bladder Cancer,” Journal of Clinical Oncology 2, no. 5 (1984): 505–531.

[492] B. Xie, J. Lin, X. Chen, et al., “CircXRN2 suppresses Tumor Progression Driven by Histone Lactylation Through Activating the Hippo Pathway in human Bladder Cancer,” Molecular Cancer 22, no. 1 (2023): 151.

[493] M. K. Gill, T. Christova, Y. Y. Zhang, et al., “A Feed Forward Loop Enforces YAP/TAZ Signaling During Tumorigenesis,” Nature Communications 9, no. 1 (2018): 3510.

[494] R. J. Rebello, C. Oing, K. E. Knudsen, et al., “Prostate Cancer,” Nature Reviews Disease Primers 7, no. 1 (2021): 9.

[495] J. F. Rodriguez-Moreno and J. Garcia-Donas, “Metastatic Prostate Cancer,” New England Journal of Medicine 378, no. 17 (2018): 1653.

[496] O. Sartor and J. S. Bono, “Metastatic Prostate Cancer,” New England Journal of Medicine 378, no. 17 (2018): 1653–1654.

[497] H. I. Scher, “Defining New Standards of Care for Men With Prostate Cancer,” Lancet 387, no. 10024 (2016): 1135–1137.

[498] G. Attard, C. Parker, R. A. Eeles, et al., “Prostate Cancer,” Lancet 387, no. 10013 (2016): 70–82.

[499] L. T. Nguyen, M. S. Tretiakova, M. R. Silvis, et al., “ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors,” Cancer Cell 27, no. 6 (2015): 797–808.

[500] T. D. Kim, F. Jin, S. Shin, et al., “Histone Demethylase JMJD2A Drives Prostate Tumorigenesis Through Transcription Factor ETV1,” Journal of Clinical Investigation 126, no. 2 (2016): 706–720.

[501] G. Wang, X. Lu, P. Dey, et al., “Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression,” Cancer Discovery 6, no. 1 (2016): 80–95.

[502] J. Xie, Y. Fan, R. Jia, F. Yang, L. Ma, and L. Li, “Yes-associated Protein Regulates the Hepatoprotective Effect of Vitamin D Receptor Activation Through Promoting Adaptive Bile Duct Remodeling in Cholestatic Mice,” Journal of Pathology 255, no. 1 (2021): 95–106.

[503] H. Kagawa, A. Javali, H. H. Khoei, et al., “Human Blastoids Model Blastocyst Development and Implantation,” Nature 601, no. 7894 (2022): 600–605.

[504] J. H. Won, J. S. Choi, and J. I. Jun, “CCN1 interacts With Integrins to Regulate Intestinal Stem Cell Proliferation and Differentiation,” Nature Communications 13, no. 1 (2022): 3117.

[505] S. Ma, Z. Meng, R. Chen, and K. L. Guan, “The Hippo Pathway: Biology and Pathophysiology,” Annual Review of Biochemistry 88 (2019): 577–604.

[506] A. W. Hong, Z. Meng, and K. L. Guan, “The Hippo Pathway in Intestinal Regeneration and Disease,” Nature Reviews Gastroenterology & Hepatology 13, no. 6 (2016): 324–337.

[507] Q. Liu, J. Li, W. Zhang, et al., “Glycogen Accumulation and Phase Separation Drives Liver Tumor Initiation,” Cell 184, no. 22 (2021): 5559–5576. e5519.

[508] F. X. Yu, B. Zhao, and K. L. Guan, “Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer,” Cell 163, no. 4 (2015): 811–828.

[509] Q. Zeng and W. Hong, “The Emerging Role of the Hippo Pathway in Cell Contact Inhibition, Organ Size Control, and Cancer Development in Mammals,” Cancer Cell 13, no. 3 (2008): 188–192.

[510] P. Yadav, B. Bhatt, and K. N. Balaji, “Selective Activation of MST1/2 Kinases by Retinoid Agonist Adapalene Abrogates AURKA-Regulated Septic Arthritis,” Journal of Immunology 206, no. 12 (2021): 2888–2899.

[511] T. Moroishi, T. Hayashi, W. W. Pan, et al., “The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity,” Cell 167, no. 6 (2016): 1525–1539. e1517.

[512] A. Britschgi, S. Duss, S. Kim, et al., “The Hippo Kinases LATS1 and 2 Control human Breast Cell Fate via Crosstalk With ERalpha,” Nature 541, no. 7638 (2017): 541–545.

[513] M. Park, J. Jin, D. Y. An, et al., “Targeting YAP Activity and Glutamine Metabolism Cooperatively Suppresses Tumor Progression by Preventing Extracellular Matrix Accumulation,” Cancer Research 84, no. 20 (2024): 3388–3401.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.